Database Query Results : , , mTOR

mTOR, mammalian target of rapamycin: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
mTOR (mechanistic target of rapamycin) is a central regulator of cell growth, proliferation, metabolism, and survival. It is a serine/threonine kinase that integrates signals from nutrients, growth factors, and cellular energy status.
mTOR promotes protein synthesis and cell growth by activating downstream targets such as S6 kinase and 4E-BP1. In cancer, this pathway can become hyperactivated, leading to uncontrolled cell proliferation.

mTor Inhibitors:
-rapamycin (Sirolimus): classic natural product mTOR inhibitor
-Curcumin
-Resveratrol
-Epigallocatechin Gallate (EGCG)
-Honokiol
Scientific Papers found: Click to Expand⟱
4774- 5-FU,  TQ,  CoQ10,    Exploring potential additive effects of 5-fluorouracil, thymoquinone, and coenzyme Q10 triple therapy on colon cancer cells in relation to glycolysis and redox status modulation
- in-vitro, CRC, NA
AntiCan↑, TumCCA↑, Apoptosis↑, eff↑, Bcl-2↓, survivin↓, P21↑, p27↑, BAX↑, Cyt‑c↑, Casp3↑, PI3K↓, Akt↓, mTOR↓, Hif1a↓, PTEN↑, AMPKα↑, PDH↑, LDHA↓, antiOx↓, ROS↑, AntiCan↑,
250- AL,    Allicin Induces p53-Mediated Autophagy in Hep G2 Human Liver Cancer Cells
- in-vitro, Liver, HepG2
P53↓, PI3K↓, mTOR↓, Bcl-2↓, AMPK↑, TSC2↑, Beclin-1↑, TumAuto↑, tumCV↓, ATG7↑, MMP↓,
1069- AL,    Allicin promotes autophagy and ferroptosis in esophageal squamous cell carcinoma by activating AMPK/mTOR signaling
- vitro+vivo, ESCC, TE1 - vitro+vivo, ESCC, KYSE-510 - in-vitro, Nor, Het-1A
TumCP↓, LC3‑Ⅱ/LC3‑Ⅰ↑, p62↓, p‑AMPK↑, mTOR↓, TumAuto↑, NCOA4↑, MDA↑, Iron↑, TumW↓, TumVol↓, ATG5↑, ATG7↑, TfR1/CD71↓, FTH1↓, ROS↑, Iron↑, Ferroptosis↑, *toxicity↓,
297- ALA,    Insights on the Use of α-Lipoic Acid for Therapeutic Purposes
- Review, BC, SkBr3 - Review, neuroblastoma, SK-N-SH - Review, AD, NA
PDH↑, TumCG↓, ROS↑, AMPK↑, EGR4↓, Half-Life↓, BioAv↝, *GSH↑, *IronCh↑, *ROS↓, *antiOx↑, *neuroP↑, *Ach↑, *lipid-P↓, *IL1β↓, *IL6↓, TumCP↓, FDG↓, Apoptosis↑, AMPK↑, mTOR↓, EGFR↓, TumCI↓, TumCMig↓, *memory↑, *BioAv↑, *BioAv↝, *other↓, *other↝, *Half-Life↓, *BioAv↑, *ChAT↑, *GlucoseCon↑,
280- ALA,    Alpha‐lipoic acid inhibits lung cancer growth via mTOR‐mediated autophagy inhibition
- in-vivo, Lung, A549
p‑mTOR↑, TumCG↓, TumAuto↓, p‑P70S6K↑,
265- ALA,    Alpha-Lipoic Acid Reduces Cell Growth, Inhibits Autophagy, and Counteracts Prostate Cancer Cell Migration and Invasion: Evidence from In Vitro Studies
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145
ROS↓, SOD↓, GSTP1/GSTπ↓, NRF2↓, p62↓, p62↑, SOD↑, p‑mTOR↑, Beclin-1↓, ROS↑, SOD1↑,
262- ALA,    Lipoic acid decreases breast cancer cell proliferation by inhibiting IGF-1R via furin downregulation
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
TumCP↓, Akt↓, ERK↓, IGF-1R↓, Furin↓, Ki-67↓, AMPK↑, mTOR↓,
1124- ALA,    Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells
- in-vitro, Thyroid, BCPAP - in-vitro, Thyroid, HTH-83 - in-vitro, Thyroid, CAL-62 - in-vitro, Thyroid, FTC-133 - in-vivo, NA, NA
TumCP↓, AMPK↑, mTOR↓, TumCMig↓, TumCI↓, EMT↓, E-cadherin↑, β-catenin/ZEB1↓, Vim↓, Snail↓, Twist↓, TGF-β↓, p‑SMAD2↓, TumCG↓,
3434- ALA,    Alpha lipoic acid modulates metabolic reprogramming in breast cancer stem cells enriched 3D spheroids by targeting phosphoinositide 3-kinase: In silico and in vitro insights
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
tumCV↓, PI3K↓, p‑Akt↓, p‑P70S6K↓, mTOR↓, ATP↓, GlucoseCon↓, ROS↑, PKM2↓, LDHA↓, Glycolysis↓, ChemoSen↑,
3454- ALA,    Lipoic acid blocks autophagic flux and impairs cellular bioenergetics in breast cancer and reduces stemness
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
TumCG↑, Glycolysis↓, ROS↑, CSCs↓, selectivity↑, LC3B-II↑, MMP↓, mitResp↓, ATP↓, OCR↓, NAD↓, p‑AMPK↑, GlucoseCon↓, lactateProd↓, HK2↓, PFK↓, LDHA↓, eff↓, mTOR↓, ECAR↓, ALDH↓, CD44↓, CD24↓,
1279- And,    Andrographolide Exhibits Anticancer Activity against Breast Cancer Cells (MCF-7 and MDA-MB-231 Cells) through Suppressing Cell Proliferation and Inducing Cell Apoptosis via Inactivation of ER-α Receptor and PI3K/AKT/mTOR Signaling
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7
Apoptosis↑, Bcl-2↓, BAX↑, ERα/ESR1↓, PI3K↓, mTOR↓,
1008- Api,    Apigenin-induced lysosomal degradation of β-catenin in Wnt/β-catenin signaling
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW480
Wnt/(β-catenin)↓, β-catenin/ZEB1↓, TumAuto↑, Akt↓, mTOR↓, tumCV↓, TumCCA↑, TumAuto↑, p‑Akt↓, p‑p70S6↓, p‑4E-BP1↓,
242- Api,    Apigenin inhibits proliferation and invasion, and induces apoptosis and cell cycle arrest in human melanoma cells
- in-vitro, Melanoma, A375 - in-vitro, Melanoma, C8161
ERK↓, PI3k/Akt/mTOR↓, Casp3↑, PARP↑, p‑mTOR↓, p‑Akt↓,
270- Api,    Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo via inactivation of Akt and activation of JNK
- in-vivo, AML, U937
Akt↓, JNK↑, Mcl-1↓, cl‑Bcl-2↓, Casp3↑, Casp7↑, Casp9↑, cl‑PARP↑, mTOR↓, GSK‐3β↓,
1545- Api,    The Potential Role of Apigenin in Cancer Prevention and Treatment
- Review, NA, NA
TNF-α↓, IL6↓, IL1α↓, P53↑, Bcl-xL↓, Bcl-2↓, BAX↑, Hif1a↓, VEGF↓, TumCCA↑, DNAdam↑, Apoptosis↑, CycB/CCNB1↓, cycA1/CCNA1↓, CDK1↓, PI3K↓, Akt↓, mTOR↓, IKKα↓, ERK↓, p‑Akt↓, p‑P70S6K↓, p‑S6↓, p‑ERK↓, p‑P90RSK↑, STAT3↓, MMP2↓, MMP9↓, TumCP↓, TumCMig↓, TumCI↓, Wnt/(β-catenin)↓,
1548- Api,    A comprehensive view on the apigenin impact on colorectal cancer: Focusing on cellular and molecular mechanisms
- Review, Colon, NA
*BioAv↓, *Half-Life∅, selectivity↑, *toxicity↓, Wnt/(β-catenin)↓, P53↑, P21↑, PI3K↓, Akt↓, mTOR↓, TumCCA↑, TumCI↓, TumCMig↓, STAT3↓, PKM2↓, EMT↓, cl‑PARP↑, Casp3↑, Bax:Bcl2↑, VEGF↓, Hif1a↓, Dose∅, GLUT1↓, GlucoseCon↓,
1565- Api,    Apigenin-7-glucoside induces apoptosis and ROS accumulation in lung cancer cells, and inhibits PI3K/Akt/mTOR pathway
- in-vitro, Lung, A549 - in-vitro, Nor, BEAS-2B - in-vitro, Lung, H1975
TumCP↓, Apoptosis↑, TumCMig↓, TumCI↓, Cyt‑c↑, MDA↑, GSH↓, ROS↑, PI3K↓, Akt↓, mTOR↓,
2584- Api,  Chemo,    The versatility of apigenin: Especially as a chemopreventive agent for cancer
- Review, Var, NA
ChemoSen↑, RadioS↑, eff↝, DR5↑, selectivity↑, angioG↓, selectivity↑, chemoP↑, MAPK↓, PI3K↓, Akt↓, mTOR↓, Wnt↓, β-catenin/ZEB1↓, GLUT1↓, radioP↑, BioAv↓, chemoPv↑,
2631- Api,    Apigenin Induces Autophagy and Cell Death by Targeting EZH2 under Hypoxia Conditions in Gastric Cancer Cells
- in-vivo, GC, NA - in-vitro, GC, AGS
ER Stress↑, Hif1a↓, EZH2↓, HDAC↓, TumAuto↑, p‑mTOR↓, AMPKα↑, GRP78/BiP↑, ROS↑, MMP↓, Ca+2↑, ATF4↑, CHOP↑,
3396- ART/DHA,    Progress on the study of the anticancer effects of artesunate
- Review, Var, NA
TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, Diff↑, TumAuto↑, angioG↓, TumCCA↑, ROS↑, AMPK↑, mTOR↑, ChemoSen↑, Tf↑, Ferroptosis↑, Ferritin↓, lipid-P↑, CDK1↑, CDK2↑, CDK4↑, CDK6↑, SIRT1↑, COX2↓, IL1β↓, survivin↓, DNAdam↑, RadioS↑,
2324- ART/DHA,    Research Progress of Warburg Effect in Hepatocellular Carcinoma
- Review, Var, NA
PKM2↓, GLUT1↓, Glycolysis↓, Akt↓, mTOR↓, Hif1a↓, HK2↓, LDH↓, NF-kB↓,
1076- ART/DHA,    The Potential Mechanisms by which Artemisinin and Its Derivatives Induce Ferroptosis in the Treatment of Cancer
- Review, NA, NA
Ferroptosis↑, ROS↑, ER Stress↑, i-Iron↓, TumAuto↑, AMPK↑, mTOR↑, P70S6K↑, Fenton↑, lipid-P↑, ROS↑, ChemoSen↑, NRF2↑, NRF2↓,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, KDR/FLK-1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1/CCND1↓, cycE1↓, CDK4/6↓, p16↑, p27↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,
558- ART/DHA,    Artemisinin and Its Synthetic Derivatives as a Possible Therapy for Cancer
- Review, NA, NA
ROS↑, oncosis↑, Apoptosis↑, LysoPr↑, TumAuto↑, Wnt/(β-catenin)↑, AMP↓, NF-kB↓, Myc↓, CREBBP↓, mTOR↓, E-cadherin↑,
566- ART/DHA,  2DG,    Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells
- in-vitro, Lung, A549 - in-vitro, Lung, PC9
GlucoseCon↓, ATP↓, lactateProd↓, p‑S6↓, mTOR↓, GLUT1↓, Casp9↑, Casp8↑, Casp3↑, Cyt‑c↑, AIF↑, ROS↑,
1335- AS,    Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, SkBr3
p‑PI3K↓, p‑GS3Kβ↓, p‑Akt↓, p‑mTOR↓,
1357- Ash,    Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways
- in-vitro, GBM, U87MG - in-vitro, GBM, U251 - in-vitro, GBM, GL26
TumCP↓, TumCCA↑, Akt↓, mTOR↓, p70S6↓, p85S6K↓, AMPKα↑, TSC2↑, HSP70/HSPA5↑, HO-1↑, HSF1↓, Apoptosis↑, ROS↑, eff↓,
4678- Ash,    Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer
- vitro+vivo, NSCLC, H1975
ROS↑, AntiTum↑, CSCs↓, mTOR↓, STAT3↓, ChemoSen↑, Keap1↑, NRF2↓,
3155- Ash,    Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera
- Review, Var, NA
Half-Life↝, Inflam↓, antiOx↓, angioG↓, ROS↑, BAX↑, Bak↑, E6↓, E7↓, P53↑, Casp3↑, cl‑PARP↑, STAT3↓, eff↑, HSP90↓, TGF-β↓, TNF-α↓, EMT↑, mTOR↓, NOTCH1↓, p‑Akt↓, NF-kB↓, Dose↝,
3166- Ash,    Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives
- Review, Var, NA
*p‑PPARγ↓, *cardioP↑, *AMPK↑, *BioAv↝, *Half-Life↝, *Half-Life↝, *Dose↑, *chemoPv↑, IL6↓, STAT3↓, ROS↓, OXPHOS↓, PCNA↓, LDH↓, AMPK↑, TumCCA↑, NOTCH3↓, Akt↓, Bcl-2↓, Casp3↑, Apoptosis↑, eff↑, NF-kB↓, CSCs↓, HSP90↓, PI3K↓, FOXO3↑, β-catenin/ZEB1↓, N-cadherin↓, EMT↓, FASN↓, ACLY↓, ROS↑, NRF2↑, HO-1↑, NQO1↑, JNK↑, mTOR↓, neuroP↑, *TNF-α↓, *IL1β↓, *IL6↓, *IL8↓, *IL18↓, RadioS↑, eff↑,
1532- Ba,    Baicalein as Promising Anticancer Agent: A Comprehensive Analysis on Molecular Mechanisms and Therapeutic Perspectives
- Review, NA, NA
ROS↑, ER Stress↑, Ca+2↑, MMPs↓, Cyt‑c↑, Casp3↑, ROS↑, DR5↑, ROS↑, BAX↑, Bcl-2↓, MMP↓, Casp3↑, Casp9↑, P53↑, p16↑, P21↑, p27↑, HDAC10↑, MDM2↓, Apoptosis↑, PI3K↓, Akt↓, p‑Akt↓, p‑mTOR↓, NF-kB↓, p‑IκB↓, IκB↑, BAX↑, Bcl-2↓, ROS⇅, BNIP3↑, p38↑, 12LOX↓, Mcl-1↓, Wnt?, GLI2↓, AR↓, eff↑,
2047- BA,    Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells
- in-vitro, CRC, T24 - in-vitro, Nor, SV-HUC-1 - in-vitro, Bladder, 5637 - in-vivo, NA, NA
HDAC↓, AntiTum↑, TumCMig↓, AMPK↑, mTOR↑, TumAuto↑, ROS↑, miR-139-5p↑, BMI1↓, TumCI?, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, cl‑PARP↑, cl‑Casp3↑, BAX↑, Bcl-2↓, Bcl-xL↓, MMP↓, PINK1↑, PARK2↑, TumMeta↓, TumCG↓, LC3II↑, p62↓, eff↓,
2599- Ba,    Baicalein induces apoptosis and autophagy of breast cancer cells via inhibiting PI3K/AKT pathway in vivo and vitro
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
TumCP↓, Apoptosis↑, p‑Akt↓, p‑mTOR↓, NF-kB↓, p‑IKKα↓, IKKα↑, PI3K↓, MMP↓, TumAuto↑, TumVol↓, TumW↓,
2603- Ba,    Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumCG↓, Apoptosis↑, Cav1↓, p‑Akt↓, p‑mTOR↓, Bax:Bcl2↑, survivin↓, cl‑PARP↑, BioAv↓,
2618- Ba,    Baicalein induces apoptosis by inhibiting the glutamine-mTOR metabolic pathway in lung cancer
- in-vitro, Lung, H1299 - in-vivo, Lung, A549
TumCG↓, TumCP↓, Apoptosis↑, GLUT1↓, GLS↓, mTOR↓, *toxicity∅, cl‑Casp9↓, cl‑Casp3↓, GSH↓, GlutMet↓,
2617- Ba,    Potential of baicalein in the prevention and treatment of cancer: A scientometric analyses based review
- Review, Var, NA
Ca+2↑, MMP2↓, MMP9↓, Vim↓, Snail↓, E-cadherin↑, Wnt↓, β-catenin/ZEB1↓, p‑Akt↓, p‑mTOR↓, NF-kB↓, i-ROS↑, Bcl-2↓, BAX↑, Cyt‑c↑, Casp3↑, Casp9↑, STAT3↓, IL6↓, MMP2↓, MMP9↓, NOTCH↓, PPARγ↓, p‑NRF2↓, HK2↓, LDHA↓, PDK1↓, Glycolysis↓, PTEN↑, Akt↓, Hif1a↓, MMP↓, VEGF↓, VEGFR2↓, TOP2↓, uPA↓, TIMP1↓, TIMP2↓, cMyc↓, TrxR↓, ASK1↑, Vim↓, ZO-1↑, E-cadherin↑, SOX2↓, OCT4↓, Shh↓, Smo↓, Gli1↓, N-cadherin↓, XIAP↓,
2615- Ba,    The Multifaceted Role of Baicalein in Cancer Management through Modulation of Cell Signalling Pathways
- Review, Var, NA
*AntiCan↓, *Inflam↓, TumCP↓, NF-kB↓, PPARγ↑, TumCCA↑, JAK2↓, STAT3↓, TumCMig↓, Glycolysis↓, MMP2↓, MMP9↓, selectivity↑, VEGF↓, Hif1a↓, cMyc↓, ChemoSen↑, ROS↑, p‑mTOR↓, PTEN↑,
2290- Ba,    Research Progress of Scutellaria baicalensis in the Treatment of Gastrointestinal Cancer
- Review, GI, NA
p‑mTOR↓, p‑Akt↓, p‑IKKα↓, NF-kB↓, PI3K↓, Akt↓, ROCK1↓, GSK‐3β↓, CycB/CCNB1↓, cycD1/CCND1↓, cycA1/CCNA1↑, CDK4↓, P53↑, P21↑, TumCCA↑, MMP2↓, MMP9↓, EMT↓, Hif1a↓, Shh↓, PD-L1↓, STAT3↓, IL1β↓, IL2↓, IL6↓, PKM2↓, HDAC10↓, P-gp↓, Bcl-xL↓, eff↓, BioAv↓, BioAv↑,
2292- Ba,  BA,    Baicalin and baicalein in modulating tumor microenvironment for cancer treatment: A comprehensive review with future perspectives
- Review, Var, NA
AntiCan↑, *toxicity↓, BioAv↝, BioAv↓, *ROS↓, *TLR2↓, *NF-kB↓, *NRF2↑, *antiOx↑, *Inflam↓, HDAC1↓, HDAC8↓, Wnt↓, β-catenin/ZEB1↓, PD-L1↓, Sepsis↓, NF-kB↓, LOX1↓, COX2↓, VEGF↑, PI3K↓, Akt↓, mTOR↓, MMP2↓, MMP9↓, SIRT1↑, AMPK↑,
2296- Ba,    The most recent progress of baicalein in its anti-neoplastic effects and mechanisms
- Review, Var, NA
CDK1↓, Cyc↓, p27↑, P21↑, P53↑, TumCCA↑, TumCI↓, MMP2↓, MMP9↓, E-cadherin↑, N-cadherin↓, Vim↓, LC3A↑, p62↓, p‑mTOR↓, PD-L1↓, CAFs/TAFs↓, VEGF↓, ROCK1↓, Bcl-2↓, Bcl-xL↓, BAX↑, ROS↑, cl‑PARP↑, Casp3↑, Casp9↑, PTEN↑, MMP↓, Cyt‑c↑, Ca+2↑, PERK↑, IRE1↑, CHOP↑, Copper↑, Snail↓, Vim↓, Twist↓, GSH↓, NRF2↓, HO-1↓, GPx4↓, XIAP↓, survivin↓, DR5↑,
2021- BBR,    Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways
- Review, NA, NA
*antiOx?, *Inflam↓, Apoptosis↑, TumCCA↑, BAX↑, eff↑, VEGF↓, PI3K↓, Akt↓, mTOR↓, Telomerase↓, β-catenin/ZEB1↓, Wnt↓, EGFR↓, AP-1↓, NF-kB↓, COX2↑, NRF2↓, RadioS↑, STAT3↓, ERK↓, AR↓, ROS↑, eff↑, selectivity↑, selectivity↑, BioAv↓, DNMT1↓, cMyc↓,
1387- BBR,    Antitumor Activity of Berberine by Activating Autophagy and Apoptosis in CAL-62 and BHT-101 Anaplastic Thyroid Carcinoma Cell Lines
- in-vitro, Thyroid, CAL-62
TumCG↓, Apoptosis↑, LC3B↑, ROS↑, PI3K↓, Akt↓, mTOR↓,
2696- BBR,    Berberine regulates proliferation, collagen synthesis and cytokine secretion of cardiac fibroblasts via AMPK-mTOR-p70S6K signaling pathway
- in-vivo, Nor, NA
*α-SMA↓, *TGF-β1↓, *IL10↑, *p‑AMPK↑, *p‑mTOR↓, *P70S6K↓, *cardioP↑,
2698- BBR,    A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine berberine
- Analysis, BC, MDA-MB-231
HDAC↓, Akt↓, mTOR↓, ER Stress↑, TumAuto↑, AMPK↑, mTOR∅, HDAC∅, ac‑α-tubulin↑,
2707- BBR,    Berberine exerts its antineoplastic effects by reversing the Warburg effect via downregulation of the Akt/mTOR/GLUT1 signaling pathway
- in-vitro, Liver, HepG2 - in-vitro, BC, MCF-7
GLUT1↓, Akt↓, mTOR↓, ATP↓, GlucoseCon↓, TumCP↓, Warburg↓, selectivity↑, TumCCA↑, Glycolysis↓,
2708- BBR,    Berberine decelerates glucose metabolism via suppression of mTOR‑dependent HIF‑1α protein synthesis in colon cancer cells
- in-vitro, CRC, HCT116
TumCG↓, GlucoseCon↓, GLUT1↓, LDHA↓, HK2↓, Hif1a↓, mTOR↓, Glycolysis↓,
2674- BBR,    Berberine: A novel therapeutic strategy for cancer
- Review, Var, NA - Review, IBD, NA
Inflam↓, AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumMeta↓, TumCI↓, eff↑, eff↑, CD4+↓, TNF-α↓, IL1↓, BioAv↓, BioAv↓, other↓, AMPK↑, MAPK↓, NF-kB↓, IL6↓, MCP1↓, PGE2↓, COX2↓, *ROS↓, *antiOx↑, *GPx↑, *Catalase↑, AntiTum↑, TumCP↓, angioG↓, Fas↑, FasL↑, ROS↑, ATM↑, P53↑, RB1↑, Casp9↑, Casp8↑, Casp3↓, BAX↑, Bcl-2↓, Bcl-xL↓, IAP1↓, XIAP↓, survivin↓, MMP2↓, MMP9↓, CycB/CCNB1↓, CDC25↓, CDC25↓, Cyt‑c↑, MMP↓, RenoP↑, mTOR↓, MDM2↓, LC3II↑, ERK↓, COX2↓, MMP3↓, TGF-β↓, EMT↑, ROCK1↓, FAK↓, RAS↓, Rho↓, NF-kB↓, uPA↓, MMP1↓, MMP13↓, ChemoSen↑,
2677- BBR,    Liposome-Encapsulated Berberine Alleviates Liver Injury in Type 2 Diabetes via Promoting AMPK/mTOR-Mediated Autophagy and Reducing ER Stress: Morphometric and Immunohistochemical Scoring
- in-vivo, Diabetic, NA
*hepatoP↑, *LC3II↑, *Beclin-1↑, *AMPK↑, *mTOR↑, *ER Stress↓, *CHOP↓, *JNK↓, *ROS↓, *Inflam↓, *BG↓, *SOD↑, *GPx↑, *Catalase↑, *IL10↑, *IL6↓, *TNF-α↓, *ALAT↓, *AST↓, *ALP↓,
2678- BBR,    Berberine as a Potential Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
*Inflam↓, *antiOx↑, *cardioP↑, *neuroP↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDC2↓, AMPK↝, mTOR↝, Casp8↑, Casp9↑, Cyt‑c↑, TumCMig↓, TumCI↓, EMT↓, MMPs↓, E-cadherin↓, Telomerase↓, *toxicity↓, GRP78/BiP↓, EGFR↓, CDK4↓, COX2↓, PGE2↓, p‑JAK2↓, p‑STAT3↓, MMP2↓, MMP9↓, GutMicro↑, eff↝, *BioAv↓, BioAv↑,
2682- BBR,    Berberine Inhibited Growth and Migration of Human Colon Cancer Cell Lines by Increasing Phosphatase and Tensin and Inhibiting Aquaporins 1, 3 and 5 Expressions
- in-vitro, CRC, HT29 - in-vitro, CRC, SW480 - in-vitro, CRC, HCT116
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, necrosis↑, AQPs↓, PTEN↑, PI3K↓, Akt↓, p‑Akt↓, mTOR↓, p‑mTOR↓,
3680- BBR,    Network pharmacology reveals that Berberine may function against Alzheimer’s disease via the AKT signaling pathway
- in-vivo, AD, NA
*Akt↑, *neuroP↑, *p‑ERK↑, *Aβ↓, *Inflam↓, *ROS↓, *BioAv↑, *BBB↑, *Half-Life↝, *memory↑, *cognitive↑, *HSP90↑, *APP↓, *mTOR↓, *P70S6K↓, *CD31↑, *VEGF↑, *N-cadherin↑, *Apoptosis↓,
2736- BetA,  Chemo,    Multifunctional Roles of Betulinic Acid in Cancer Chemoprevention: Spotlight on JAK/STAT, VEGF, EGF/EGFR, TRAIL/TRAIL-R, AKT/mTOR and Non-Coding RNAs in the Inhibition of Carcinogenesis and Metastasis
- Review, Var, NA
chemoPv↑, p‑STAT3↓, JAK1↓, JAK2↓, VEGF↓, EGFR↓, Cyt‑c↑, Diablo↑, AMPK↑, mTOR↓, Sp1/3/4↓, DNAdam↑, Gli1↓, GLI2↓, PTCH1↓, MMP2↓, MMP9↓, miR-21↓, SOD2↓, ROS↑, Apoptosis↑,
2730- BetA,    Betulinic acid induces autophagy-dependent apoptosis via Bmi-1/ROS/AMPK-mTOR-ULK1 axis in human bladder cancer cells
- in-vitro, Bladder, T24
tumCV↓, TumCP↓, TumCMig↓, Casp↑, TumAuto↑, LC3B-II↑, p‑AMPK↑, mTOR↓, BMI1↓, ROS↑, eff↓,
1416- Bos,    Anti-cancer properties of boswellic acids: mechanism of action as anti-cancerous agent
- Review, NA, NA
5LO↓, TumCCA↑, LC3B↓, PI3K↓, Akt↓, Glycolysis↓, AMPK↑, mTOR↓, Let-7↑, COX2↓, VEGF↓, CXCR4↓, MMP2↓, MMP9↓, HIF-1↓, angioG↓, TumCP↓, TumCMig↓, NF-kB↓,
2776- Bos,    Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities
- Review, Var, NA
*5LO↓, *TNF-α↓, *MMP3↓, *COX1↓, *COX2↓, *PGE2↓, *Th2↑, *Catalase↑, *SOD↑, *NO↑, *PGE2↑, *IL1β↓, *IL6↓, *Th1 response↓, *Th2↑, *iNOS↓, *NO↓, *p‑JNK↓, *p38↓, GutMicro↑, p‑Akt↓, GSK‐3β↓, cycD1/CCND1↓, Akt↓, STAT3↓, CSCs↓, AR↓, P21↑, DR5↑, CHOP↑, Casp3↑, Casp8↑, cl‑PARP↑, DNAdam↑, p‑RB1↓, FOXM1↓, TOP2↓, CDC25↓, p‑CDK1↓, p‑ERK↓, MMP9↓, VEGF↓, angioG↓, ROS↑, Cyt‑c↑, AIF↑, Diablo↑, survivin↓, ICAD↓, ChemoSen↑, SOX9↓, ER Stress↑, GRP78/BiP↑, cal2↓, AMPK↓, mTOR↓, ROS↓,
1101- CA,  Tras,    Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2+ breast cancer cells
- in-vitro, BC, NA
ChemoSen↑, HER2/EBBR2↓, PI3K↓, Akt↓, mTOR↓, p62↑,
2017- CAP,    Spice Up Your Kidney: A Review on the Effects of Capsaicin in Renal Physiology and Disease
- Review, Var, NA
RenoP↑, AntiTum↑, AMPK↑, mTOR↑, PD-1↓, PD-L1↓,
2018- CAP,  MF,    Capsaicin: Effects on the Pathogenesis of Hepatocellular Carcinoma
- Review, HCC, NA
TRPV1↑, eff↑, Akt↓, mTOR↓, p‑STAT3↑, MMP2↑, ER Stress↑, Ca+2↑, ROS↑, selectivity↑, MMP↓, eff↑,
2019- CAP,    Capsaicin: A Two-Decade Systematic Review of Global Research Output and Recent Advances Against Human Cancer
- Review, Var, NA
chemoPv↑, Ca+2↑, antiOx↑, *ROS↓, *MMP∅, *Cyt‑c∅, *Casp3∅, *eff↑, *Inflam↓, *NF-kB↓, *COX2↓, iNOS↓, TRPV1↑, i-Ca+2?, MMP↓, Cyt‑c↑, Bax:Bcl2↑, P53↑, JNK↑, PI3K↓, Akt↓, mTOR↓, LC3II↑, ATG5↑, p62↑, Fap1↓, Casp3↑, Apoptosis↑, ROS↑, MMP9↓, eff↑, eff↓, eff↑, selectivity↑, eff↑, ChemoSen↑,
1145- CHr,    Chrysin inhibits propagation of HeLa cells by attenuating cell survival and inducing apoptotic pathways
- in-vitro, Cerv, HeLa
tumCV↓, BAX↑, BID↑, BOK↑, APAF1↑, TNF-α↑, FasL↑, Fas↑, FADD↑, Casp3↑, Casp7↑, Casp8↑, Casp9↑, Mcl-1↓, NAIP↓, Bcl-2↓, CDK4↓, CycB/CCNB1↓, cycD1/CCND1↓, cycE1↓, TRAIL↑, p‑Akt↓, Akt↓, mTOR↓, PDK1↓, BAD↓, GSK‐3β↑, AMPK↑, p27↑, P53↑,
2781- CHr,  PBG,    Chrysin a promising anticancer agent: recent perspectives
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, MMP9↑, uPA↓, VEGF↓, AR↓, Casp↑, TumMeta↓, TumCCA↑, angioG↓, BioAv↓, *hepatoP↑, *neuroP↑, *SOD↑, *GPx↑, *ROS↓, *Inflam↓, *Catalase↑, *MDA↓, ROS↓, BBB↑, Half-Life↓, BioAv↑, ROS↑, eff↑, ROS↑, ROS↑, lipid-P↑, ER Stress↑, NOTCH1↑, NRF2↓, p‑FAK↓, Rho↓, PCNA↓, COX2↓, NF-kB↓, PDK1↓, PDK3↑, GLUT1↓, Glycolysis↓, mt-ATP↓, Ki-67↓, cMyc↓, ROCK1↓, TOP1↓, TNF-α↓, IL1β↓, CycB/CCNB1↓, CDK2↓, EMT↓, STAT3↓, PD-L1↓, IL2↑,
2785- CHr,    Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin
- Review, Var, NA
*NF-kB↓, *COX2↓, *iNOS↓, angioG↓, TOP1↓, HDAC↓, TNF-α↓, IL1β↓, cardioP↑, RenoP↑, neuroP↑, LDL↓, BioAv↑, eff↑, cycD1/CCND1↓, hTERT/TERT↓, MMP-10↓, Akt↓, STAT3↓, VEGF↓, EGFR↓, Snail↓, Slug↓, Vim↓, E-cadherin↑, eff↑, TET1↑, ROS↑, mTOR↓, PPARα↓, ER Stress↑, Ca+2↑, ERK↓, MMP↑, Cyt‑c↑, Casp3↑, HK2↓, NRF2↓, HO-1↓, MMP2↓, MMP9↓, Fibronectin↓, GRP78/BiP↑, XBP-1↓, p‑eIF2α↑, *AST↓, ALAT↓, ALP↓, LDH↓, COX2↑, Bcl-xL↓, IL6↓, PGE2↓, iNOS↓, DNAdam↑, UPR↑, Hif1a↓, EMT↓, Twist↓, lipid-P↑, CLDN1↓, PDK1↓, IL10↓, TLR4↓, NOTCH1↑, PARP↑, Mcl-1↓, XIAP↓,
2315- Citrate,    Why and how citrate may sensitize malignant tumors to immunotherapy
- Review, Var, NA
Bcl-2↓, Mcl-1↓, survivin↓, Casp3↑, Casp9↑, Ferroptosis↑, lipid-P↑, Ca+2↓, Akt↓, mTOR↓, Hif1a↓, MCU↓, ATP↓, ROS↑, eff↑,
1578- Citrate,    Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update
- Review, Var, NA
TCA↑, FASN↑, Glycolysis↓, glucoNG↑, PFK1↓, PFK2↓, FBPase↑, TumCP↓, eff↑, ACLY↓, Dose↑, Casp3↑, Casp2↑, Casp8↑, Casp9↑, Bcl-xL↓, Mcl-1↓, IGF-1R↓, PI3K↓, Akt↓, mTOR↓, PTEN↑, ChemoSen↑, Dose?,
1580- Citrate,    Citrate activates autophagic death of prostate cancer cells via downregulation CaMKII/AKT/mTOR pathway
- in-vitro, Pca, PC3 - in-vivo, PC, NA - in-vitro, Pca, LNCaP - in-vitro, Pca, WPMY-1
Apoptosis↑, Ca+2↓, Akt↓, mTOR↓, selectivity↑, TumCP↓, cl‑Casp3↑, cl‑PARP↑, LC3‑Ⅱ/LC3‑Ⅰ↑, p62↓, ATG5↑, ATG7↑, Beclin-1↑, TumAuto↑, CaMKII ↓,
1585- Citrate,    Sodium citrate targeting Ca2+/CAMKK2 pathway exhibits anti-tumor activity through inducing apoptosis and ferroptosis in ovarian cancer
- in-vitro, Ovarian, SKOV3 - in-vitro, Ovarian, A2780S - in-vitro, Nor, HEK293
Apoptosis↑, Ferroptosis↑, Ca+2↓, CaMKII ↓, Akt↓, mTOR↓, Hif1a↓, ROS↑, ChemoSen↑, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, Cyt‑c↑, GlucoseCon↓, lactateProd↓, Pyruv↓, GLUT1↓, HK2↓, PFKP↓, Glycolysis↓, Hif1a↓, p‑Akt↓, p‑mTOR↓, Iron↑, lipid-P↑, MDA↑, ROS↑, H2O2↑, mtDam↑, GSH↓, GPx↓, GPx4↓, NADPH/NADP+↓, eff↓, FTH1↓, LC3‑Ⅱ/LC3‑Ⅰ↑, NCOA4↑, eff↓, TumCG↓,
4776- CoQ10,    Antitumor properties of Coenzyme Q0 against human ovarian carcinoma cells via induction of ROS-mediated apoptosis and cytoprotective autophagy
- vitro+vivo, Ovarian, SKOV3
ROS↑, eff↓, AntiCan↑, Apoptosis↑, tumCV↓, TumCG↓, TumCCA↑, LC3s↑, ERStress↑, Beclin-1↑, Bax:Bcl2↑, HER2/EBBR2↓, Akt↓, mTOR↓,
4773- CoQ10,    Coenzyme Q10 inhibits the activation of pancreatic stellate cells through PI3K/AKT/mTOR signaling pathway
- in-vitro, Nor, NA
*other↓, *PI3K↑, *Akt↑, *mTOR↑, *ROS↓,
3631- Croc,    Investigation of the neuroprotective effects of crocin via antioxidant activities in HT22 cells and in mice with Alzheimer's disease
- in-vitro, AD, HT22 - in-vivo, AD, NA
*ROS↓, *Ca+2↓, *BAX↓, *BAD↓, *Casp3↓, *cognitive↑, *memory↑, *Aβ↓, *GPx↑, *SOD↑, *ChAT↑, *Ach↑, *AChE↓, *ROS↓, *p‑Akt↑, *p‑mTOR↑, *neuroP↑,
3861- CUR,    Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment?
- Review, Var, NA
*antiOx↑, *Inflam↓, PI3K↓, Akt↓, mTOR↓, Wnt↓, β-catenin/ZEB1↓, NF-kB↓, HH↓, NOTCH↓, JAK↓, STAT3↓, ADAM10↓,
3795- CUR,    Curcumin: A Golden Approach to Healthy Aging: A Systematic Review of the Evidence
- Review, AD, NA
*antiOx↑, *Inflam↓, *AntiAge↑, *AMPK↑, *SIRT1↑, *NF-kB↓, *mTOR↓, *NLRP3↓, *NADPH↓, *ROS↓, *COX2↓, *MCP1↓, *IL1β↓, *IL17↓, *IL23↓, *TNF-α↓, *MPO↓, *IL10↑, *lipid-P↓, *SOD↑, *Aβ↓, *p‑tau↓, *GSK‐3β↓, *CDK5↓, *TXNIP↓, *NRF2↑, *NQO1↑, *HO-1↑, *OS↑, *memory↑, *BDNF↑, *neuroP↑, *BACE↓, *AChE↓, *LDL↓,
2304- CUR,    Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition
- in-vitro, Lung, H1299 - in-vitro, BC, MCF-7 - in-vitro, Cerv, HeLa - in-vitro, Pca, PC3 - in-vitro, Nor, HEK293
Glycolysis↓, GlucoseCon↓, lactateProd↓, PKM2↓, mTOR↓, Hif1a↓, selectivity↑, Dose↝, tumCV↓,
2307- CUR,    Cell-Type Specific Metabolic Response of Cancer Cells to Curcumin
- in-vitro, Colon, HT29 - in-vitro, Laryn, FaDu
PKM2↓, Warburg↓, mTOR↓, Hif1a↓, Glycolysis↓,
2821- CUR,    Antioxidant curcumin induces oxidative stress to kill tumor cells (Review)
- Review, Var, NA
*antiOx↑, *NRF2↑, *ROS↓, *Inflam↓, ROS↑, p‑ERK↑, ER Stress↑, mtDam↑, Apoptosis↑, Akt↓, mTOR↓, HO-1↑, Fenton↑, GSH↓, Iron↑, p‑JNK↑, Cyt‑c↑, ATF6↑, CHOP↑,
4710- CUR,    mTOR_signaling_pathway">Curcumin inhibits migration and invasion of non-small cell lung cancer cells through up-regulation of miR-206 and suppression of PI3K/AKT/mTOR signaling pathway
- in-vitro, Lung, A549
TumCMig↓, TumCI↓, miR-206↑, p‑mTOR↓, p‑Akt↓,
140- CUR,    Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling
- in-vitro, Pca, PC3
CAFs/TAFs↓, EMT↓, ROS↓, CXCR4↓, IL6↓, MAOA↓, mTOR↓, HIF-1↓,
15- CUR,  UA,    Effects of curcumin and ursolic acid in prostate cancer: A systematic review
NF-kB↝, Akt↝, AR↝, Apoptosis↝, Bcl-2↝, Casp3↝, BAX↝, P21↝, ROS↝, Apoptosis↝, Bcl-xL↝, JNK↝, MMP2↝, P53↝, PSA↝, VEGF↝, COX2↝, cycD1/CCND1↝, EGFR↝, IL6↝, β-catenin/ZEB1↝, mTOR↝, NRF2↝, p‑Akt↝, AP-1↝, Cyt‑c↝, PI3K↝, PTEN↝, Cyc↝, TNF-α↝,
168- CUR,    Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism
- in-vitro, Pca, PC3
Akt↓, mTOR↓, AMPK↑, TAp63α↑,
425- CUR,    Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells
- in-vitro, BC, T47D - in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
CDC25↓, cDC2↓, P21↑, p‑Akt↓, p‑mTOR↓, Bcl-2↓, BAX↑, Casp3↑,
435- CUR,    Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway
- in-vitro, Lung, A549
Apoptosis↑, TumAuto↑, LC3‑Ⅱ/LC3‑Ⅰ↑, Beclin-1↑, p62↓, PI3K↓, Akt↓, mTOR↓, p‑Akt↓, p‑mTOR↓,
471- CUR,    Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT/mTOR/p70S6K pathway in human ovarian cancer cells
- in-vitro, Ovarian, SKOV3 - in-vitro, Ovarian, A2780S
Apoptosis↑, TumAuto↑, p62↓, p‑Akt↓, p‑mTOR↓, p‑P70S6K↓, Casp9↑, PARP↑, ATG3↑, Beclin-1↑, LC3‑Ⅱ/LC3‑Ⅰ↑,
476- CUR,    The effects of curcumin on proliferation, apoptosis, invasion, and NEDD4 expression in pancreatic cancer
- in-vitro, PC, PATU-8988 - in-vitro, PC, PANC1
TumCMig↓, TumCI↓, Apoptosis↑, NEDD9↓, p‑Akt↓, p‑mTOR↓, PTEN↑, p73↑, β-TRCP↑,
445- CUR,    Curcumin Regulates the Progression of Colorectal Cancer via LncRNA NBR2/AMPK Pathway
- in-vitro, CRC, HCT116 - in-vitro, CRC, HCT8 - in-vitro, CRC, SW480 - in-vitro, CRC, SW-620
p‑AMPK↑, p‑ACC-α↑, NBR2↑, p‑S6K↓, mTOR↓,
452- CUR,    Curcumin downregulates the PI3K-AKT-mTOR pathway and inhibits growth and progression in head and neck cancer cells
- vitro+vivo, HNSCC, SCC9 - vitro+vivo, HNSCC, FaDu - vitro+vivo, HNSCC, HaCaT
TumCCA↑, PI3k/Akt/mTOR↓, Casp3↑, EGFR↓, EGF↑, PRKCG↑, p‑Akt↓, p‑mTOR↓, RPS6KA1↓, EIF4E↓, proCasp3↓,
457- CUR,    Curcumin regulates proliferation, autophagy, and apoptosis in gastric cancer cells by affecting PI3K and P53 signaling
- in-vitro, GC, SGC-7901 - in-vitro, GC, BGC-823
TumCP↓, Apoptosis↑, TumAuto↑, P53↑, PI3K↓, P21↑, p‑Akt↓, p‑mTOR↓, Bcl-2↓, Bcl-xL↓, LC3I↓, BAX↑, Beclin-1↑, cl‑Casp3↑, cl‑PARP↑, LC3II↑, ATG3↑, ATG5↑,
1869- DCA,    Dichloroacetate induces autophagy in colorectal cancer cells and tumours
- in-vitro, CRC, HT-29 - in-vitro, CRC, HCT116 - in-vitro, Pca, PC3 - in-vitro, CRC, HT-29
LC3II↑, ROS↑, mTOR↓, MCT1↓, NADH:NAD↓, NAD↑, TumAuto↑, lactateProd↓, LDH↑,
4901- DCA,  Sal,    Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer
- Review, NSCLC, NA
Glycolysis↓, OXPHOS↑, PDKs↓, ROS↑, Apoptosis↑, GlucoseCon↓, lactateProd↓, RadioS↑, TumAuto↑, mTOR↓, LC3s↓, p62↑, TumCG↓, OS↑, toxicity↝, ChemoSen↑, eff↑, eff↑, Ferritin↓, CSCs↓, EMT↓, ROS↑, Cyt‑c↑, Casp3↑, ER Stress↑, selectivity↑, eff↑, TumCG↓,
19- Deg,    Deguelin inhibits proliferation and migration of human pancreatic cancer cells in vitro targeting hedgehog pathway
- in-vitro, PC, Bxpc-3 - in-vitro, PC, PANC1
HH↓, Gli1↓, PTCH1↓, Sufu↓, MMP2↓, MMP9↓, PI3K/Akt↓, HIF-1↓, VEGF↓, IKKα↓, NF-kB↓, EMT↓, AMPK↑, mTOR↓, survivin↓,
1442- Deg,    Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention
- Review, Var, NA
PI3K/Akt↓, IKKα↓, AMP↓, mTOR↓, survivin↓, NF-kB↓, Apoptosis↑, TumCCA↑, toxicity↓, HSP90↓, Casp↑, TumCG↓, p27↑, cycE/CCNE↓, angioG↓, Hif1a↓, VEGF↓, *toxicity↑,
1854- dietFMD,    How Far Are We from Prescribing Fasting as Anticancer Medicine?
- Review, Var, NA
ChemoSideEff↓, ChemoSen↑, IGF-1↓, IGFBP1↑, adiP↑, glyC↓, E-cadherin↑, MMPs↓, Casp3↑, ROS↑, ATP↓, AMPK↑, mTOR↓, ROS↑, Glycolysis↓, NADPH↓, OXPHOS↝, eff↑, eff↑, *RAS↓, *MAPK↓, *PI3K↓, *Akt↓, eff↑, ROS↑, Akt↑, Casp3↑,
1852- dietFMD,  Chemo,    Starvation Based Differential Chemotherapy: 
A Novel Approach for Cancer Treatment
- Review, Var, NA
ChemoSideEff↓, *toxicity↓, mTOR↓, IGF-1↓, IGFBP1↑, BG↓, ROS↑,
1849- dietFMD,    The emerging role of fasting-mimicking diets in cancer treatment
- Review, Var, NA
TumCG↓, toxicity∅, BG↓, IGF-1↓, mTOR↓, M2 MC↓, eff↑, ChemoSen↑, QoL↑, RadioS↑, selectivity↑,
1844- dietFMD,    Unlocking the Potential: Caloric Restriction, Caloric Restriction Mimetics, and Their Impact on Cancer Prevention and Treatment
- Review, NA, NA
Risk↓, AMPK↑, Akt↓, mTOR↓, SIRT1↑, Hif1a↓, NRF2↓, SOD↑, ROS↑, IGF-1↓, p‑Akt↓, PI3K↑, GutMicro↑, OS↑, eff↝, ROS↑, TumCCA↑, *DNArepair↑, DNAdam↑,
1860- dietFMD,  Chemo,    Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape
- in-vitro, BC, SUM159 - in-vitro, BC, 4T1
PI3K↑, Akt↑, mTOR↑, CDK4↑, CDK6↑, hyperG↓, TumCG↓, TumVol↓, Casp3↑, BG↓, eff↑, eff∅, PKA↓, KLF5↓, p‑GSK‐3β↑, Nanog↓, OCT4↓, KLF2↓, eff↑, ROS↑, BIM↑, ASK1↑, PI3K↑, Akt↑, mTOR↑, CDK1↓, CDK4↑, CDK6↑, eff↑,
2352- dietFMD,    Glucose restriction reverses the Warburg effect and modulates PKM2 and mTOR expression in breast cancer cell lines
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7
Warburg↓, mTOR↓, PKM2↓,
2272- dietMet,    Methionine restriction - Association with redox homeostasis and implications on aging and diseases
- Review, Nor, NA
*OS↑, *mt-ROS↓, *H2S↑, *FGF21↑, *cognitive↑, *GutMicro↑, *IGF-1↓, *mTOR↓, *GSH↑, *SOD↑, *MDA↓, *NRF2↑, *HO-1↑, *NQO1↑, *GLUT4↑, *Glycolysis↑, *HK2↑, *PFK↑, *PKM2↑, *GlucoseCon↑, *ATF4↑, *PPARα↑, GSH↓, GSTs↑, ROS↑, *neuroP↑,
3708- dietSTF,    Fasting as a Therapy in Neurological Disease
*PGC-1α↑, *AMPK↑, *adiP↑, *glucose↓, *Insulin↓, *mTOR↓, *IL6↓, *TNF-α↓, *cognitive↑, *Inflam↓, *eff↑, *neuroP↑, ChemoSen↑, eff↓, chemoP↑, *eff↑,
1608- EA,    Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity
- in-vitro, Cerv, HeLa - in-vitro, Liver, HepG2 - in-vitro, BC, MCF-7 - in-vitro, Lung, A549 - in-vitro, Nor, HUVECs
eff↑, Dose∅, *BioAv↑, selectivity↑, TumCP↓, Casp↑, PTEN↑, TSC1↑, mTOR⇅, Akt↓, PDK1↓, E6↓, E7↓, DNAdam↑, ROS↑, *BioAv↓, *BioEnh↑, *Half-Life∅,
1610- EA,    Anticancer Effect of Pomegranate Peel Polyphenols against Cervical Cancer
- Review, Cerv, NA
TumCCA↑, STAT3↓, P21↑, IGFBP7↑, Akt↓, mTOR↓, ROS↑, DNAdam↑, P53↑, P21↑, BAX↑,
20- EGCG,    Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer
- in-vivo, Liver, NA - in-vivo, Tong, NA
HH↓, Gli1↓, Smo↓, TNF-α↓, COX2↓, *antiOx↑, Hif1a↓, NF-kB↓, VEGF↓, STAT3↓, Bcl-2↓, P53↑, Akt↓, p‑Akt↓, p‑mTOR↓, EGFR↓, AP-1↓, BAX↑, ROS↑, Casp3↑, Apoptosis↑, NRF2↑, *H2O2↓, *NO↓, *SOD↑, *Catalase↑, *GPx↑, *ROS↓,
651- EGCG,    Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications
ROS↑, p‑AMPK↑, mTOR↓, FAK↓, Smo↓, Gli1↓, HH↓, TumCMig↓, TumCI↓, NOTCH↓, JAK↓, STAT↓, Bcl-2↓, Bcl-xL↓, BAX↑, Casp9↑,
694- EGCG,    Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways
- in-vitro, BC, MCF-7
Glycolysis↓, GAPDH↓, ROS↑, OCR↓, ECAR↓, mTOR↓, OXPHOS↓,
683- EGCG,    Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy
- Review, NA, NA
AMPK↑, TumCP↓, P21↑, mTOR↓, COX2↓,
682- EGCG,    Suppressive Effects of EGCG on Cervical Cancer
- Review, NA, NA
E7↓, E6↓, PI3K/Akt↓, P53↑, p27↑, P21↑, CDK2↓, mTOR↓, HIF-1↓, IGF-1↓, EGFR↓, ERK↓, VEGF↓,
3244- EGCG,    Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells
AMPK↑, TumCP↓, P21↑, mTOR↓, CSCs↓, CD44↓, CD24↓,
3214- EGCG,    EGCG-induced selective death of cancer cells through autophagy-dependent regulation of the p62-mediated antioxidant survival pathway
- in-vitro, Nor, MRC-5 - in-vitro, Cerv, HeLa - in-vitro, Nor, HEK293 - in-vitro, BC, MDA-MB-231 - in-vitro, CRC, HCT116
mTOR↓, AMPK↑, selectivity↑, ROS↑, selectivity↑, HO-1↓, *NRF2↑, NRF2↓, *HO-1↑,
1323- EMD,    Anticancer action of naturally occurring emodin for the controlling of cervical cancer
- Review, Cerv, NA
TumCCA↑, DNAdam↑, mTOR↓, Casp3↑, Casp8↑, Casp9↑, TGF-β↑, SMAD3↓, p‑SMAD4↓, ROS↑, MMP↓, CXCR4↓, HER2/EBBR2↓, ER Stress↓, TumAuto↑, NOTCH1↓,
1654- FA,    Molecular mechanism of ferulic acid and its derivatives in tumor progression
- Review, Var, NA
AntiCan↑, Inflam↓, RadioS↑, ROS↑, Apoptosis↑, TumCCA↑, TumCMig↑, TumCI↓, angioG↓, ChemoSen↑, ChemoSideEff↓, P53↑, cycD1/CCND1↓, CDK4↓, CDK6↓, TumW↓, miR-34a↑, Bcl-2↓, Casp3↑, BAX↑, β-catenin/ZEB1↓, cMyc↓, Bax:Bcl2↑, SOD↓, GSH↓, LDH↓, ERK↑, eff↑, JAK2↓, STAT6↓, NF-kB↓, PYCR1↓, PI3K↓, Akt↓, mTOR↓, Ki-67↓, VEGF↓, FGFR1↓, EMT↓, CAIX↓, LC3II↑, p62↑, PKM2↓, Glycolysis↓, *BioAv↓,
2845- FIS,    Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, p38↓, *antiOx↑, *neuroP↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, DNAdam↑, MMP↓, eff↑, ROS↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, P53↑, p65↓, Myc↓, HSP70/HSPA5↓, HSP27↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, TumCCA↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycA1/CCNA1↓, P21↑, MMP2↓, MMP9↓, TumMeta↓, MMP1↓, MMP3↓, MMP7↓, MET↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↑, uPA↓, ChemoSen↑, EMT↓, Twist↓, Zeb1↓, cFos↓, cJun↓, EGF↓, angioG↓, VEGF↓, eNOS↓, *NRF2↑, HO-1↑, NRF2↓, GSTs↓, ATF4↓,
2847- FIS,    Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells
- in-vitro, CCA, NA
tumCV↓, ChemoSen↑, TumCMig↓, ROS↑, TumCI↓, angioG↓, CDK2↓, PI3K↓, Akt↓, mTOR↓, EGFR↓, Casp↑, mTORC1↓, mTORC2↑, cycD1/CCND1↓, cycE/CCNE↓, MMP2↓, MMP9↓, ER Stress↑, Ca+2↑, eff↓,
2849- FIS,    Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells
- in-vitro, Melanoma, U266
TumCD↑, TumCCA↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, p‑Akt↓, p‑mTOR↓, ROS↑, eff↓,
2857- FIS,    A review on the chemotherapeutic potential of fisetin: In vitro evidences
- Review, Var, NA
COX2↓, PGE2↓, EGFR↓, Wnt↓, β-catenin/ZEB1↓, TCF↑, Apoptosis↑, Casp3↑, cl‑PARP↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, Akt↓, mTOR↓, ACC↑, Cyt‑c↑, Diablo↑, cl‑Casp8↑, Fas↑, DR5↑, TRAIL↑, Securin↓, CDC2↓, CDC25↓, HSP70/HSPA5↓, CDK2↓, CDK4↓, cycD1/CCND1↓, MMP2↓, uPA↓, NF-kB↓, cFos↓, cJun↓, MEK↓, p‑ERK↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↓, NF-kB↑, ROS↑, DNAdam↑, MMP↓, CHOP↑, eff↑, ChemoSen↑,
2860- FIS,    Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways
- in-vitro, PC, PANC1 - in-vitro, PC, Bxpc-3 - in-vitro, Nor, hTERT-HPNE - in-vivo, NA, NA
AMPK↑, mTOR↑, UPR↑, ER Stress↑, selectivity↑, TumCP↓, PERK↑, ATF4↑, ATF6↑,
2825- FIS,    Exploring the molecular targets of dietary flavonoid fisetin in cancer
- Review, Var, NA
*Inflam↓, *antiOx↓, *ERK↑, *p‑cMyc↑, *NRF2↑, *GSH↑, *HO-1↑, mTOR↓, PI3K↓, Akt↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, P21↑, p27↑, JNK↑, MMP2↓, MMP9↓, uPA↓, NF-kB↓, cFos↓, cJun↓, E-cadherin↑, Vim↓, N-cadherin↓, EMT↓, MMP↓, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, P53↑, COX2↓, PGE2↓, HSP70/HSPA5↓, HSP27↓, DNAdam↑, Casp3↑, Casp9↑, ROS↑, AMPK↑, NO↑, Ca+2↑, mTORC1↓, p70S6↓, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, eff↑, eff↑, eff↑, RadioS↑, ChemoSen↑, Half-Life↝,
2828- FIS,    Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review
- Review, Var, NA
*neuroP↑, *antiOx↑, *Inflam↓, RenoP↑, COX2↓, Wnt↓, EGFR↓, NF-kB↓, Casp3↑, Ca+2↑, Casp8↑, TumCCA↑, CDK1↓, PI3K↓, Akt↓, mTOR↓, MAPK↓, *P53↓, *P21↓, *p16↓, mTORC1↓, mTORC2↓, P53↑, P21↑, cycD1/CCND1↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, BAX↑, Bcl-2↓, PCNA↓, HER2/EBBR2↓, Cyt‑c↑, MMP↓, cl‑Casp9↑, MMP2↓, MMP9↓, cl‑PARP↑, uPA↓, DR4↑, DR5↑, ROS↓, AIF↑, CDC25↓, Dose↑, CHOP↑, ROS↑, cMyc↓, cardioP↑,
2829- FIS,    Fisetin: An anticancer perspective
- Review, Var, NA
TumCP↓, TumCI↓, TumCCA↑, TumCG↓, Apoptosis↑, cl‑PARP↑, PKCδ↓, ROS↓, ERK↓, NF-kB↓, survivin↓, ROS↑, PI3K↓, Akt↓, mTOR↓, MAPK↓, p38↓, HER2/EBBR2↓, EMT↓, PTEN↑, HO-1↑, NRF2↑, MMP2↓, MMP9↓, MMP↓, Casp8↑, Casp9↑, TRAILR↑, Cyt‑c↑, XIAP↓, P53↑, CDK2↓, CDK4↓, CDC25↓, CDC2↓, VEGF↓, DNAdam↑, TET1↓, CHOP↑, CD44↓, CD133↓, uPA↓, CSCs↓,
2830- FIS,    Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent
- Review, Var, NA
TumCG↓, angioG↓, *ROS↓, TumCMig↓, VEGF↓, MAPK↑, NF-kB↓, PI3K↓, Akt↓, mTOR↓, NRF2↑, HO-1↑, ROS↓, Inflam↓, ER Stress↑, ROS↑, TumCP↓, ChemoSen↑, PTEN↑, P53↑, Casp3↑, Casp8↑, Casp9↑, COX2↓, Wnt↓, EGFR↓, Mcl-1↓, survivin↓, IAP1↓, IAP2↓, PGE2↓, β-catenin/ZEB1↓, DR5↑, MMP2↓, MMP9↓, FAK↓, uPA↓, EMT↓, ERK↓, JNK↑, p38↑, PKCδ↓, BioAv↓, BioAv↑, BioAv↑,
2832- FIS,    Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies
- Review, Var, NA
MMP↓, mtDam↑, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, Bak↑, BIM↑, Bcl-xL↓, Bcl-2↓, P53↑, ROS↑, AMPK↑, Casp9↑, Casp3↑, BID↑, AIF↑, Akt↓, mTOR↓, MAPK↓, Wnt↓, β-catenin/ZEB1↓, TumCCA↑, P21↑, p27↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, TumMeta↓, uPA↓, E-cadherin↑, Vim↓, EMT↓, Twist↓, DNAdam↑, ROS↓, COX2↓, PGE2↓, HSF1↓, cFos↓, cJun↓, AP-1↓, Mcl-1↓, NF-kB↓, IRE1↑, ER Stress↑, ATF4↑, GRP78/BiP↑, MMP2↓, MMP9↓, TCF-4↓, MMP7↓, RadioS↑, TOP1↓, TOP2↓,
2839- FIS,    Dietary flavonoid fisetin for cancer prevention and treatment
- Review, Var, NA
DNAdam↑, ROS↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp9↑, cl‑Casp3↑, Cyt‑c↑, lipid-P↓, TumCG↓, TumCA↓, TumCMig↓, TumCI↓, uPA↓, ERK↓, MMP9↓, NF-kB↓, cFos↓, cJun↓, AP-1↓, TumCCA↑, AR↓, mTORC1↓, mTORC2↓, TSC2↑, EGF↓, TGF-β↓, EMT↓, P-gp↓, PI3K↓, Akt↓, mTOR↓, eff↑, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, ChemoSen↑, CDK2↓, CDK4↓, cycE/CCNE↓, cycD1/CCND1↓, P21↑, COX2↓, Wnt↓, EGFR↓, β-catenin/ZEB1↓, TCF-4↓, MMP7↓, RadioS↑, eff↑,
2843- FIS,    Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential
- Review, Var, NA
NRF2↑, Keap1↓, ChemoSen↑, BioAv↓, Cyt‑c↑, Casp3↑, Casp9↑, BAX↑, tumCV↓, Mcl-1↓, cl‑PARP↑, IGF-1↓, Akt↓, CDK6↓, TumCCA↑, P53?, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, MMP2↓, MMP9↓, MMP1↓, MMP7↓, MMP3↓, VEGF↓, PI3K↓, mTOR↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, ERK↓, ROS↑, angioG↓, TNF-α↓, PGE2↓, iNOS↓, NO↓, IL6↓, HSP70/HSPA5↝, HSP27↝,
2313- Flav,    Flavonoids against the Warburg phenotype—concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism
- Review, Var, NA
Warburg↓, antiOx↑, angioG↓, Glycolysis↓, PKM2↓, PKM2:PKM1↓, β-catenin/ZEB1↓, cMyc↓, HK2↓, Akt↓, mTOR↓, GLUT1↓, Hif1a↓,
1969- GamB,    Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells
- in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
AntiTum↑, TumCI↓, Apoptosis↑, ROS↑, Cyt‑c↑, Akt↓, mTOR↓, TumCG↓, TumMeta↓,
802- GAR,    Garcinol acts as an antineoplastic agent in human gastric cancer by inhibiting the PI3K/AKT signaling pathway
- in-vitro, GC, HGC27
TumCP↓, TumCI↓, Apoptosis↑, PI3K/Akt↓, Akt↓, p‑mTOR↓, cycD1/CCND1↓, MMP2↓, MMP9↓, BAX↑, Bcl-2↓,
3773- H2,    Role and mechanism of molecular hydrogen in the treatment of Parkinson’s diseases
- Review, Park, NA
*neuroP↑, *antiOx↑, *Inflam↓, *ROS↓, *NADPH↓, *NRF2↑, *BBB↑, *IL1β↓, *IL6↓, *TNF-α↓, *NF-kB↓, *NLRP3↓, *Sepsis↓, *p‑mTOR↓, *AMPK↑, *SIRT1↑, *HO-1↑,
3770- H2,    Role of Molecular Hydrogen in Ageing and Ageing-Related Diseases
- Review, AD, NA - Review, Park, NA
*antiOx↑, *NRF2↑, *HO-1↑, *Inflam↓, *neuroP↑, *cardioP↑, *other↓, *ROS↓, *NADPH↓, *Catalase↑, *GPx1↑, *NO↓, *mt-ROS↓, *SIRT3↑, *SIRT1↑, *TLR4↓, *mTOR↓, *cognitive↑, *Sepsis↓, *PTEN↓, *Akt↓, *NLRP3↓, *AntiAg↑, *IL6↓, *TNF-α↓, *IL1β↓, *MDA↓, *memory↑, *FOXO3↑, TumCG↓, *LDL↓,
2507- H2,    Hydrogen protects against chronic intermittent hypoxia induced renal dysfunction by promoting autophagy and alleviating apoptosis
- in-vivo, NA, NA
*RenoP↑, *ROS↓, *Apoptosis↓, *ER Stress↓, *CHOP↓, *Casp12↓, *GRP78/BiP↓, *LC3‑Ⅱ/LC3‑Ⅰ↑, *Beclin-1↑, *p62↓, *mTOR↓,
292- HCA,    Hydroxycitric Acid Inhibits Chronic Myelogenous Leukemia Growth through Activation of AMPK and mTOR Pathway
- in-vitro, AML, K562
ACLY↓, AMPK↑, mTOR↑, eIF2α↑, ATFs↑, TumCG↓,
2894- HNK,    Pharmacological features, health benefits and clinical implications of honokiol
- Review, Var, NA - Review, AD, NA
*BioAv↓, *neuroP↑, *BBB↑, *ROS↓, *Keap1↑, *NRF2↑, *Casp3↓, *SIRT3↑, *Rho↓, *ERK↓, *NF-kB↓, angioG↓, RAS↓, PI3K↓, Akt↓, mTOR↓, *memory↑, *Aβ↓, *PPARγ↑, *PGC-1α↑, NF-kB↓, Hif1a↓, VEGF↓, HO-1↓, FOXM1↓, p27↑, P21↑, CDK2↓, CDK4↓, CDK6↓, cycD1/CCND1↓, Twist↓, MMP2↓, Rho↑, ROCK1↑, TumCMig↓, cFLIP↓, BMPs↑, OCR↑, ECAR↓, *AntiAg↑, *cardioP↑, *antiOx↑, *ROS↓, P-gp↓,
2883- HNK,    Honokiol targets mitochondria to halt cancer progression and metastasis
- Review, Var, NA
ChemoSen↑, BBB↓, Ca+2↑, Cyt‑c↑, Casp3↑, chemoPv↑, OCR↓, mitResp↓, Apoptosis↑, RadioS↑, NF-kB↓, Akt↓, TNF-α↓, PGE2↓, VEGF↓, NO↝, COX2↓, RAS↓, EMT↓, Snail↓, N-cadherin↓, β-catenin/ZEB1↓, E-cadherin↑, ER Stress↑, p‑STAT3↓, EGFR↓, mTOR↓, mt-ROS↑, PI3K↓, Wnt↓,
2885- HNK,    Honokiol: a novel natural agent for cancer prevention and therapy
NF-kB↓, STAT3↓, EGFR↓, mTOR↓, BioAv↝, Inflam↓, TumCP↓, angioG↓, TumCI↓, TumMeta↓, cSrc↓, JAK1↓, JAK2↓, ERK↓, Akt↓, PTEN↑, ChemoSen↑, chemoP↑, COX2↓, PGE2↓, TNF-α↓, IL1β↓, IL6↓, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, DNAdam↑, Cyt‑c↑, RadioS↑, RAS↓, BBB↑, BioAv↓, Half-Life↝, Half-Life↝, toxicity↓,
2888- HNK,    Honokiol mediated inhibition of PI3K/mTOR pathway: A potential strategy to overcome immunoresistance in glioma, breast and prostate carcinoma without impacting T cell function
- in-vitro, Var, PC3 - in-vitro, BC, BT549
PI3K↓, mTOR↓, Inflam↓,
2892- HNK,    Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells
- in-vitro, Lung, A549 - in-vitro, Lung, H460 - in-vitro, Lung, H385 - in-vitro, Nor, BEAS-2B
TumCCA↑, Apoptosis↑, SIRT3↑, Hif1a↓, selectivity↑, p‑mTOR↓, p70S6↓,
2891- HNK,    Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs
- Review, Var, NA
AntiCan↑, Inflam↓, antiOx↑, selectivity↑, *toxicity↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, TumMeta↓, NADPH↓, MMP2↓, MMP9↓, p‑mTOR↓, EGFR↓, EMT↓, SIRT1↑, SIRT3↑, EZH2↓, Snail↓, Vim↓, N-cadherin↓, E-cadherin↑, COX2↓, NF-kB↓, *ROS↓, Ca+2↑, ROS↑,
2868- HNK,    Honokiol: A review of its pharmacological potential and therapeutic insights
- Review, Var, NA - Review, Sepsis, NA
*P-gp↓, *ROS↓, *TNF-α↓, *IL10↓, *IL6↓, eIF2α↑, CHOP↑, GRP78/BiP↑, BAX↑, cl‑Casp9↑, p‑PERK↑, ER Stress↑, Apoptosis↑, MMPs↓, cFLIP↓, CXCR4↓, Twist↓, HDAC↓, BMPs↑, p‑STAT3↓, mTOR↓, EGFR↓, NF-kB↓, Shh↓, VEGF↓, tumCV↓, TumCMig↓, TumCI↓, ERK↓, Akt↓, Bcl-2↓, Nestin↓, CD133↓, p‑cMET↑, RAS↑, chemoP↑, *NRF2↑, *NADPH↓, *p‑Rac1↓, *ROS↓, *IKKα↑, *NF-kB↓, *COX2↓, *PGE2↓, *Casp3↓, *hepatoP↑, *antiOx↑, *GSH↑, *Catalase↑, *RenoP↑, *ALP↓, *AST↓, *ALAT↓, *neuroP↑, *cardioP↑, *HO-1↑, *Inflam↓,
4688- HNK,    Honokiol Suppresses Renal Cancer Cells’ Metastasis via Dual-Blocking Epithelial-Mesenchymal Transition and Cancer Stem Cell Properties through Modulating miR-141/ZEB2 Signaling
- vitro+vivo, RCC, A498
CSCs↓, EMT↓, TumCG↓, PI3K↓, Akt↓, mTOR↓, p‑Akt↓, PTEN↑, Wnt↓, β-catenin/ZEB1↓,
4640- HT,    The anti-cancer potential of hydroxytyrosol
- Review, Var, NA
selectivity↑, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, Bcl-2↓, BAX↑, MPT↑, Fas↑, PI3K↓, Akt↓, mTOR↓, Mcl-1↓, survivin↓, STAT3↓, EMT↓, TumCI↓, angioG↓, E-cadherin↑, N-cadherin↓, Snail↓, Twist↓, MMPs↓, MMP2↓, MMP9↓, VEGF↓, VEGFR2↓, Hif1a↓, CSCs↓, CD44↓, Wnt↓, β-catenin/ZEB1↓,
4212- Hup,    Huperzine A Alleviates Oxidative Glutamate Toxicity in Hippocampal HT22 Cells via Activating BDNF/TrkB-Dependent PI3K/Akt/mTOR Signaling Pathway
- in-vitro, Nor, HT22
*ROS↓, *p‑Akt↓, *p‑mTOR↓, *p‑p70S6↓, *BDNF↑, *Apoptosis↓, *Casp3↓, *Bcl-2↑,
2180- itraC,    Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
- Review, Var, NA
Dose↝, toxicity↝, BioAv↑, Half-Life↝, BioAv↑, Dose↝, HH↓, TumAuto↑, Akt↓, mTOR↓, angioG↓, MDR1↓, TumCP↓, eff↑,
2179- itraC,    Repurposing itraconazole for the treatment of cancer
- Review, Var, NA
HH↓, angioG↓, TumCCA↑, MDR1↓, P-gp↓, mTOR↓, VEGF↓, Smo↓, Gli1↓, OS↑, PSA↓,
1168- IVM,  SRF,    Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways
- in-vitro, HCC, NA
TumMeta↓, mTOR↓, EMT↓, CSCsMark↓, STAT3↓,
1918- JG,    ROS -mediated p53 activation by juglone enhances apoptosis and autophagy in vivo and in vitro
- in-vitro, Liver, HepG2 - in-vivo, NA, NA
TumCG↓, TumCP↓, Apoptosis↑, TumAuto↑, AMPK↑, mTOR↑, P53↑, H2O2↑, ROS↑, toxicity↝, p62↓, DR5↑, Casp8↑, PARP↑, cl‑Casp3↑,
862- Lae,    Molecular mechanism of amygdalin action in vitro: review of the latest research
- Review, NA, NA
BAX↑, Casp3↑, Bcl-2↓, Akt↓, mTOR↓, p19↑, TumCCA↑, other↓,
4293- LT,    Regulatory Role of NF-κB on HDAC2 and Tau Hyperphosphorylation in Diabetic Encephalopathy and the Therapeutic Potential of Luteolin
- in-vivo, Diabetic, NA
*Inflam↓, *antiOx↑, *neuroP↑, *cognitive↑, *p‑mTOR↓, *p‑NF-kB↓, *HDAC2↓, *BDNF↑, *other↓, *p‑tau↓,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
3275- Lyco,    Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-Based Treatment for Cancer
- Review, Var, NA
TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, P21↑, P53↑, GSK‐3β↓, p27↓, Akt↓, mTOR↓, ROS↓, MMPs↓, TumCI↓, TumCMig↓, NF-kB↓, *iNOS↓, *COX2↓, lipid-P↓, GSH↑, NRF2↑,
3265- Lyco,    Lycopene inhibits pyroptosis of endothelial progenitor cells induced by ox-LDL through the AMPK/mTOR/NLRP3 pathway
- in-vitro, Nor, NA
*AMPK↑, *mTOR↓, *NLRP3↓, *Pyro↓,
4800- Lyco,    Recent insights on pharmacological potential of lycopene and its nanoformulations: an emerging paradigm towards improvement of human health
- Review, Var, NA
*antiOx↑, Keap1↝, NF-kB↝, NRF2↝, PI3K↝, Akt↝, mTOR↝, *GutMicro↑,
4791- Lyco,    Investigating into anti-cancer potential of lycopene: Molecular targets
- Review, Var, NA
*antiOx↑, TumCP↓, TumCCA↓, Apoptosis↑, TumCI↓, angioG↓, TumMeta↓, *Risk↓, cycD1/CCND1↓, CycD3↓, cycE/CCNE↓, CDK2↓, CDK4↓, Bcl-2↓, P21↑, p27↑, P53↑, BAX↑, selectivity↑, MMP↓, Cyt‑c↑, Wnt↓, eff↑, PPARγ↑, LDL↓, Akt↓, PI3K↓, mTOR↓, PDGF↓, NF-kB↓, eff↑,
4786- Lyco,    Anti-proliferative and apoptosis-inducing activity of lycopene against three subtypes of human breast cancer cell lines
- in-vitro, BC, MDA-MB-468 - in-vitro, BC, MCF-7 - in-vitro, BC, SkBr3
TumCP↓, TumCCA↑, cl‑PARP↑, ERK↑, cycD1/CCND1↓, P21↓, p‑Akt↓, mTOR↓, BAX↑, AntiCan↑, Risk↓,
1126- Lyco,    Lycopene Inhibits Epithelial–Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway
- vitro+vivo, Oral, NA
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, EMT↓, PI3K↓, Akt↓, mTOR↓, E-cadherin↓, BAX↑, N-cadherin↓, p‑PI3K↓, p‑Akt↓, p‑mTOR↓, Bcl-2↓,
2540- M-Blu,    Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots
- Review, Var, NA - Review, AD, NA
*OCR↑, *Glycolysis↓, *GlucoseCon↑, neuroP↑, Warburg↓, mt-OXPHOS↑, TumCCA↑, TumCP↓, ROS⇅, *cognitive↑, *mTOR↓, *mt-antiOx↑, *memory↑, *BBB↑, *eff↝, *ECAR↓, eff↑, lactateProd↓, NADPH↓, OXPHOS↑, AMPK↑, selectivity↑,
972- MAG,    Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells
- vitro+vivo, Bladder, T24
angioG↓, VEGF↓, H2O2↓, Hif1a↓, VEGFR2↓, Akt↓, mTOR↓, P70S6K↓, 4E-BP1↓, TumCG↓, CD31↓, CA↓,
4514- MAG,    Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential
- Review, Var, NA
AntiCan↑, TumCP↓, TumCCA↑, TumMeta↓, angioG↓, NF-kB↓, MAPK↓, PI3K↓, Akt↓, mTOR↓, BioAv↓, *antiOx↑, *Inflam↓, *AntiAg↑, ChemoSen↑, cycD1/CCND1↓, CycB/CCNB1↓, cycE/CCNE↓, CDK2↓, CDK4↓, p27↑, P21↑, P53↑, PTEN↓, XIAP↓, Mcl-1↓, Casp3↑, Casp9↑, MMP9↑,
4535- MAG,  5-FU,    Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K/AKT/mTOR and EMT pathways
- in-vitro, Cerv, NA
ChemoSen↑, TumCP↓, vinculin↓, TumCA↓, TumCMig↓, TumCI↓, p‑Akt↓, p‑PI3K↓, mTOR↓, E-cadherin↑, β-catenin/ZEB1↑, Snail↓, Slug↓,
4528- MAG,    Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update
- Review, Nor, NA
*Inflam↑, *cardioP↑, *angioG↓, *antiOx↑, *neuroP↑, *Bacteria↓, AntiTum↑, TumCG↓, TumCMig↓, TumCI↓, Apoptosis↑, E-cadherin↑, NF-kB↓, TumCCA↑, cycD1/CCND1↓, PCNA↓, Ki-67↓, MMP2↓, MMP7↓, MMP9↓, TumCG↓, Casp3↑, NF-kB↓, Akt↓, mTOR↓, LDH↓, Ca+2↑, eff↑, *toxicity↓, *BioAv↝, *PGE2↓, *TLR2↓, *TLR4↓, *MAPK↓, *PPARγ↓,
4515- MAG,    Magnolol as a Potential Anticancer Agent: A Proposed Mechanistic Insight
- Review, Var, NA
AntiCan↑, TumCP↓, TumCCA↑, Apoptosis↑, TumCMig↑, angioG↓, PI3K↓, Akt↓, mTOR↓, MAPK↓, NF-kB↓,
2643- MCT,    Medium Chain Triglycerides enhances exercise endurance through the increased mitochondrial biogenesis and metabolism
- Review, Nor, NA
*Akt↑, *AMPK↓, *TGF-β↓, eff↑, *BioEnh↑, *ATP↑, *PGC-1α↑, *p‑mTOR↑, *SMAD3↓,
2386- MET,    Mechanisms of metformin inhibiting cancer invasion and migration
- Review, Var, NA
OS↑, AMPK↑, EMT↓, TGF-β↓, mTOR↓, P70S6K↓, PKM2↓, Hif1a↓, ChemoSen↑,
2378- MET,    Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway
- in-vitro, SCC, CAL27 - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,
2377- MET,    Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells
- in-vitro, Cerv, HeLa - in-vitro, Cerv, SiHa
EMT↓, P70S6K↓, mTOR↓, PKM2↓, Warburg↓, AMPK↑,
2374- MET,    Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions
- in-vitro, BC, MCF-7 - in-vitro, BC, SkBr3 - in-vitro, BC, MDA-MB-231
eff↑, Apoptosis↑, Glycolysis↓, PKM2↓, mTOR↓, PARP↓,
2243- MF,    Pulsed electromagnetic fields increase osteogenetic commitment of MSCs via the mTOR pathway in TNF-α mediated inflammatory conditions: an in-vitro study
- in-vitro, Nor, NA
*eff↑, *mTOR↑, *Akt↑, *PKA↑, *MAPK↑, *ERK↑, *BMP2↑, *Diff↑, *PKCδ↓, *VEGF↑, *IL10↑,
3480- MF,    Cellular and Molecular Effects of Magnetic Fields
- Review, NA, NA
ROS↑, *Ca+2↑, *Inflam↓, *Akt↓, *mTOR↓, selectivity↑, *memory↑, *MMPs↑, *VEGF↑, *FGF↑, *PDGF↑, *TNF-α↑, *HGF/c-Met↑, *IL1↑,
3741- MF,    Promising application of Pulsed Electromagnetic Fields (PEMFs) in musculoskeletal disorders
- Review, NA, NA
*eff↑, *BMD↑, *Inflam↓, *PGE2↓, *IL6↓, *IL8↓, *NF-kB↓, *mTOR↝,
486- MF,    mTOR Activation by PI3K/Akt and ERK Signaling in Short ELF-EMF Exposed Human Keratinocytes
- in-vitro, Nor, HaCaT
*mTOR↑, *PI3K↑, *Akt↑, *p‑ERK↑, *other↑, *p‑JNK↑, *p‑P70S6K↑,
3488- MFrot,  MF,    Rotating magnetic field improves cognitive and memory impairments in APP/PS1 mice by activating autophagy and inhibiting the PI3K/AKT/mTOR signaling pathway
- in-vivo, AD, NA
*cognitive↑, *memory↑, *neuroP↑, *Aβ↓, *PI3K↓, *Akt↓, *mTOR↓,
3745- MFrot,  MF,    The neurobiological foundation of effective repetitive transcranial magnetic brain stimulation in Alzheimer's disease
- Review, AD, NA
*neuroP↑, *ROS↓, *Inflam↓, *5HT↑, *cFos↑, *Aβ↓, *memory↑, *BDNF↑, *Ach↑, *AChE↓, *cognitive↑, *BDNF↑, *NGF↑, *β-catenin/ZEB1↑, *p‑Akt↓, *mTOR↓, *MMP1↓, *MMP9↓, *MMP-10↓, *TIMP1↑, *TIMP2↑,
1807- NarG,    A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies
- Review, NA, NA
AntiTum↑, TumCP↓, tumCV↓, TumCCA↑, Mcl-1↓, RAS↓, e-Raf↓, VEGF↓, AntiAg↑, MMP2↓, MMP9↓, TIMP2↑, TIMP1↑, p38↓, Wnt↓, β-catenin/ZEB1↑, Casp↑, P53↑, BAX↑, COX2↓, GLO-I↓, CYP1A1↑, lipid-P↓, p‑Akt↓, p‑mTOR↓, VCAM-1↓, P-gp↓, survivin↓, Bcl-2↓, ROS↑, ROS↑, MAPK↑, STAT3↓, chemoP↑,
1803- NarG,    Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: Efficacy and molecular mechanisms of action, a comprehensive narrative review
- Review, Var, NA
JAK↓, STAT↓, PI3K↓, Akt↓, mTOR↓, NF-kB↓, COX2↓, NOTCH↓, TumCCA↑,
1799- NarG,    Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics
- Review, NA, NA
TumCCA↑, BioAv↑, Half-Life∅, TNF-α↓, Casp8↑, BAX↑, Bak↑, EGF↓, mTOR↓, PI3K↓, ERK↓, Akt↓, NF-kB↓, VEGF↓, angioG↓, antiOx↑, EMT↓, OS↑, MAPK↓, ChemoSen↑, MMP9↓, MMP2↓, ROS↑, ROS↑, GSH↓, Casp3↑, ROS↑,
1271- NCL,    Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics
- vitro+vivo, Ovarian, SKOV3
Wnt/(β-catenin)↓, mTOR↓, STAT3↓, NF-kB↓, NOTCH↓, TumCG↓, Apoptosis↑, MEK↓, ERK↓, mitResp↓, Glycolysis↓, ROS↑, JNK↑,
4643- OLE,  HT,    Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine
- Review, Var, NA
TumCCA↑, Apoptosis↑, ER Stress↑, UPR↑, CHOP↑, ROS↑, Bcl-2↓, NOX4↑, Hif1a↓, MMP2↓, MMP↓, VEGF↓, Akt↓, NF-kB↓, p65↓, SIRT3↓, mTOR↓, Catalase↓, SOD2↓, FASN↓, STAT3↓, HDAC2↓, HDAC3↓, BAD↑, BAX↑, Bak↑, Casp3↑, Casp9↑, PARP↑, P53↑, P21↑, p27↑, Half-Life↝, BioAv↓, BioAv↓, selectivity↑, RadioS↑, *ROS↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *NRF2↑, *chemoP↑, *Inflam↓, PPARγ↑,
4647- OLEC,    Oleocanthal, an Antioxidant Phenolic Compound in Extra Virgin Olive Oil (EVOO): A Comprehensive Systematic Review of Its Potential in Inflammation and Cancer
- Review, Var, NA
*Inflam↓, AntiCan↑, *COX2↓, *ROS↓, *TNF-α↓, *IL1β↓, *iNOS↓, TumCP↓, *AntiAg↑, mTOR↓, STAT3↓, ERK↓, p‑Akt↓, Bcl-2↓, ROS↑, PSA↓,
1993- Part,    Parthenolide induces apoptosis and autophagy through the suppression of PI3K/Akt signaling pathway in cervical cancer
- in-vitro, Cerv, HeLa
tumCV↓, TumAuto↑, Casp3↑, BAX↑, Beclin-1↑, ATG3↑, ATG5↑, Bcl-2↓, mTOR↓, PI3K↓, Akt↓, PTEN↑, ROS↑, MMP↓,
1678- PBG,  5-FU,  sericin,    In vitro and in vivo anti-colorectal cancer effect of the newly synthesized sericin/propolis/fluorouracil nanoplatform through modulation of PI3K/AKT/mTOR pathway
- in-vitro, CRC, Caco-2 - in-vivo, NA, NA
PI3K↓, Akt↓, mTOR↓, TumCP↓, Bcl-2↓, BAX↑, Casp3↑, Casp9↑, ROS↓, FOXO1↑, *toxicity∅, eff↑,
4920- PEITC,  Cisplatin,    PEITC restores chemosensitivity in cisplatin-resistant non-small cell lung cancer by targeting c-Myc/miR-424-5p
- vitro+vivo, NSCLC, A549
TumCG↓, ChemoSen↑, cMyc↓, PI3K↓, Akt↓, mTOR↓, BioAv↝, tumCV↓, ChemoSen↑,
1946- PL,  PI,    Piperlonguminine and Piperine Analogues as TrxR Inhibitors that Promote ROS and Autophagy and Regulate p38 and Akt/mTOR Signaling
- in-vitro, Liver, NA
eff↑, toxicity↓, TrxR↓, ROS↑, MMP↓, p38↑, Akt↓, mTOR↓,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
2946- PL,    Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
- Review, Var, NA
ROS↑, GSH↓, DNAdam↑, ChemoSen↑, RadioS↑, BioEnh↑, selectivity↑, BioAv↓, eff↑, p‑Akt↓, mTOR↓, GSK‐3β↓, β-catenin/ZEB1↓, HK2↓, Glycolysis↓, Cyt‑c↑, Casp9↑, Casp3↑, Casp7↑, cl‑PARP↑, TrxR↓, ER Stress↑, ATF4↝, CHOP↑, Prx4↑, NF-kB↓, cycD1/CCND1↓, CDK4↓, CDK6↓, p‑RB1↓, RAS↓, cMyc↓, TumCCA↑, selectivity↑, STAT3↓, NRF2↑, HO-1↑, PTEN↑, P-gp↓, MDR1↓, MRP1↓, survivin↓, Twist↓, AP-1↓, Sp1/3/4↓, STAT1↓, STAT6↓, SOX4↑, XBP-1↑, P21↑, eff↑, Inflam↓, COX2↓, IL6↓, MMP9↓, TumMeta↓, TumCI↓, ICAM-1↓, CXCR4↓, VEGF↓, angioG↓, Half-Life↝, BioAv↑,
2944- PL,    Piperlongumine, a Potent Anticancer Phytotherapeutic, Induces Cell Cycle Arrest and Apoptosis In Vitro and In Vivo through the ROS/Akt Pathway in Human Thyroid Cancer Cells
- in-vitro, Thyroid, IHH4 - in-vitro, Thyroid, 8505C - in-vivo, NA, NA
ROS↑, selectivity↑, tumCV↓, TumCCA↑, Apoptosis↑, ERK↑, Akt↓, mTOR↓, neuroP↑, Bcl-2↓, Casp3↑, PARP↑, JNK↑, *toxicity↓, eff↓, TumW↓,
2970- PL,    Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways
- in-vitro, AML, NA
AntiAg↑, TumCG↓, Apoptosis↑, PI3K↓, Akt↓, mTOR↓, p38↑, Casp3↑,
2651- Plum,    Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence
- Review, Var, NA
ROS↑, TrxR↓, GSR↓, ER Stress↓, TumCCA↑, MMP↓, NF-kB↓, PI3K↓, Akt↓, mTOR↓, MKP1↓, MKP2↓, ChemoSen↑,
5034- PTS,    Pterostilbene in Cancer Therapy
- Review, Var, NA
BioAv↓, Half-Life↓, iNOS↓, Apoptosis↑, STAT3↓, Akt↓, mTOR↓, NF-kB↓, NRF2↓, ChemoSen↑, BBB↑,
4704- PTS,  Cisplatin,    Pterostilbene Sensitizes Cisplatin-Resistant Human Bladder Cancer Cells with Oncogenic HRAS
- in-vitro, Bladder, NA
PI3K↓, mTOR↓, P70S6K↓, MEK↑, ERK↑, ChemoSen↑, TumAuto↑,
4694- PTS,    Pterostilbene as a Multifaceted Anticancer Agent: Molecular Mechanisms, Therapeutic Potential and Future Directions
BioAv↑, AntiCan↑, Casp↑, TumCCA↑, angioG↓, TumMeta↓, MMP9↓, VEGF↓, CSCs↓, CD44↓, cMyc↓, ChemoSen↑, mTOR↓,
1237- PTS,    Pterostilbene induces cell apoptosis and inhibits lipogenesis in SKOV3 ovarian cancer cells by activation of AMPK-induced inhibition of Akt/mTOR signaling cascade
- in-vitro, Ovarian, SKOV3
TumCMig↓, TumCI↓, MDA↑, ROS↑, BAX↑, Casp3↑, Bcl-2↓, SREBP1↓, FASN↓, AMPK↓, p‑AMPK↑, p‑P53↑, p‑TSC2↑, p‑Akt↓, p‑mTOR↓, p‑S6K↓, p‑4E-BP1↓,
3354- QC,    Quercetin: Its Main Pharmacological Activity and Potential Application in Clinical Medicine
- Review, Var, NA
*ROS↓, *IronCh↓, *lipid-P↓, *GSH↑, *NRF2↑, TumCCA↑, ER Stress↑, P53↑, CDK2↓, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, cycD1/CCND1↓, PCNA↓, P21↑, p27↑, PI3K↓, Akt↓, mTOR↓, STAT3↓, cFLIP↓, cMyc↓, survivin↓, DR5↓, *Inflam↓, *IL6↓, *IL8↓, COX2↓, 5LO↓, *cardioP↑, *FASN↓, *AntiAg↑, *MDA↓,
3369- QC,    Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects
- Review, Pca, NA
FAK↓, TumCCA↑, p‑pRB↓, CDK2↑, CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt↓, ROS↑, miR-21↑, Akt↓, NF-kB↓, FasL↑, Bak↑, BAX↑, Bcl-2↓, Casp3↓, Casp9↑, P53↑, p38↑, MAPK↑, Cyt‑c↑, PARP↓, CHOP↑, ROS↓, LDH↑, GRP78/BiP↑, ERK↑, MDA↓, SOD↑, GSH↑, NRF2↑, VEGF↓, PDGF↓, EGF↓, FGF↓, TNF-α↓, TGF-β↓, VEGFR2↓, EGFR↓, FGFR1↓, mTOR↓, cMyc↓, MMPs↓, LC3B-II↑, Beclin-1↑, IL1β↓, CRP↓, IL10↓, COX2↓, IL6↓, TLR4↓, Shh↓, HER2/EBBR2↓, NOTCH↓, DR5↑, HSP70/HSPA5↓, CSCs↓, angioG↓, MMP2↓, MMP9↓, IGFBP3↑, uPA↓, uPAR↓, RAS↓, Raf↓, TSP-1↑,
3368- QC,    The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiCan↑, Casp3↓, p‑Akt↓, p‑mTOR↓, p‑ERK↓, β-catenin/ZEB1↓, Hif1a↓, AntiAg↓, VEGFR2↓, EMT↓, EGFR↓, MMP2↓, MMP↓, TumMeta↓, MMPs↓, Akt↓, Snail↓, N-cadherin↓, Vim↓, E-cadherin↑, STAT3↓, TGF-β↓, ROS↓, P53↑, BAX↑, PKCδ↓, PI3K↓, COX2↓, cFLIP↓, cycD1/CCND1↓, cMyc↓, IL6↓, IL10↓, Cyt‑c↑, TumCCA↑, DNMTs↓, HDAC↓, ac‑H3↑, ac‑H4↑, Diablo↑, Casp3↑, Casp9↑, PARP1↑, eff↑, PTEN↑, VEGF↓, NO↓, iNOS↓, ChemoSen↑, eff↑, eff↑, eff↑, uPA↓, CXCR4↓, CXCL12↓, CLDN2↓, CDK6↓, MMP9↓, TSP-1↑, Ki-67↓, PCNA↓, ROS↑, ER Stress↑,
2342- QC,    Quercetin Inhibits the Proliferation of Glycolysis-Addicted HCC Cells by Reducing Hexokinase 2 and Akt-mTOR Pathway
- in-vitro, HCC, Bel-7402 - in-vitro, HCC, SMMC-7721 cell - in-vivo, NA, NA
TumCP↓, HK2↓, Akt↓, mTOR↓, GlucoseCon↓, lactateProd↓, Glycolysis↓,
2341- QC,    Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
MMP2↓, MMP9↓, VEGF↓, Glycolysis↓, lactateProd↓, PKM2↓, GLUT1↓, LDHA↓, TumAuto↑, Akt↓, mTOR↓, TumMeta↓, MMP3↓, eff↓, GlucoseCon↓, lactateProd↓, TumAuto↑, LC3B-II↑,
63- QC,    Quercetin facilitates cell death and chemosensitivity through RAGE/PI3K/AKT/mTOR axis in human pancreatic cancer cells
- in-vitro, Pca, NA
RAGE↓, PI3K↓, mTOR↓, Akt↓, Apoptosis↑, TumAuto↑,
39- QC,    A Comprehensive Analysis and Anti-Cancer Activities of Quercetin in ROS-Mediated Cancer and Cancer Stem Cells
- Analysis, NA, NA
ROS↑, GSH↓, IL6↓, COX2↓, IL8↓, iNOS↓, TNF-α↓, MAPK↑, ERK↑, SOD↑, ATP↓, Casp↑, PI3K/Akt↓, mTOR↓, NOTCH1↓, Bcl-2↓, BAX↑, IFN-γ↓, TumCP↓, TumCCA↑, Akt↓, P70S6K↓, *Keap1↓, *GPx↑, *Catalase↑, *HO-1↑, *NRF2↑, NRF2↑, eff↑, HIF-1↓,
92- QC,    Quercetin Inhibits Angiogenesis Mediated Human Prostate Tumor Growth by Targeting VEGFR- 2 Regulated AKT/mTOR/P70S6K Signaling Pathways
- vitro+vivo, Pca, HUVECs - vitro+vivo, Pca, PC3
VEGF↓, HemoG↓, Akt↓, mTOR↓, P70S6K↓,
916- QC,    Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells
- Review, Ovarian, NA
COX2↓, CRP↓, ER Stress↑, Apoptosis↑, GRP78/BiP↑, CHOP↑, p‑STAT3↓, PI3K↓, Akt↓, mTOR↓, cMyc↓, cycD1/CCND1↓, cFLIP↓, IL6↓, IL10↓,
919- QC,    Quercetin Regulates Sestrin 2-AMPK-mTOR Signaling Pathway and Induces Apoptosis via Increased Intracellular ROS in HCT116 Colon Cancer Cells
- in-vitro, CRC, HCT116
Apoptosis↑, ROS↑, SESN2↑, P53↑, AMPKα↑, mTOR↓,
923- QC,    Quercetin as an innovative therapeutic tool for cancer chemoprevention: Molecular mechanisms and implications in human health
- Review, Var, NA
ROS↑, GSH↓, Ca+2↝, MMP↓, Casp3↑, Casp8↑, Casp9↑, other↓, *ROS↓, *NRF2↑, HO-1↑, TumCCA↑, Inflam↓, STAT3↓, DR5↑, P450↓, MMPs↓, IFN-γ↓, IL6↓, COX2↓, IL8↓, iNOS↓, TNF-α↓, cl‑PARP↑, Apoptosis↑, P53↑, Sp1/3/4↓, survivin↓, TRAILR↑, Casp10↑, DFF45↑, TNFR 1↑, Fas↑, NF-kB↓, IKKα↓, cycD1/CCND1↓, Bcl-2↓, BAX↑, PI3K↓, Akt↓, E-cadherin↓, Vim↓, β-catenin/ZEB1↓, cMyc↓, EMT↓, MMP2↓, NOTCH1↓, MMP7↓, angioG↓, TSP-1↑, CSCs↓, XIAP↓, Snail↓, Slug↓, LEF1↓, P-gp↓, EGFR↓, GSK‐3β↓, mTOR↓, RAGE↓, HSP27↓, VEGF↓, TGF-β↓, COL1↓, COL3A1↓,
910- QC,    The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism
tumCV↓, Apoptosis↑, PI3k/Akt/mTOR↓, Wnt/(β-catenin)↓, MAPK↝, ERK↝, TumCCA↑, H2O2↑, ROS↑, TumAuto↑, MMPs↓, P53↑, Casp3↑, Hif1a↓, cFLIP↓, IL6↓, IL10↓, lactateProd↓, Glycolysis↓, PKM2↓, GLUT1↓, COX2↓, VEGF↓, OCR↓, ECAR↓, STAT3↓, MMP2↓, MMP9:TIMP1↓, mTOR↓,
1490- RES,    Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues
- Review, Var, NA
TumCCA↑, ROS↑, Ca+2↑, MMP↓, ATP↓, TOP1?, P53↑, p53 Wildtype∅, Akt↓, mTOR↓, EMT↓, *BioAv↓,
2328- RES,    Resveratrol Inhibits Cancer Cell Metabolism by Down Regulating Pyruvate Kinase M2 via Inhibition of Mammalian Target of Rapamycin
- in-vitro, Cerv, HeLa - in-vitro, Liver, HepG2 - in-vitro, BC, MCF-7
PKM2↓, mTOR↓, GlucoseCon↓, lactateProd↓,
2332- RES,    Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism
- Review, Var, NA
Glycolysis↓, GLUT1↓, PFK1↓, Hif1a↓, ROS↑, PDH↑, AMPK↑, TumCG↓, TumCI↓, TumCP↓, p‑NF-kB↓, SIRT1↑, SIRT3↑, LDH↓, PI3K↓, mTOR↓, PKM2↓, R5P↝, G6PD↓, TKT↝, talin↓, HK2↓, GRP78/BiP↑, GlucoseCon↓, ER Stress↑, Warburg↓, PFK↓,
2334- RES,    Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy
- Review, Var, NA
GLUT1↓, GlucoseCon↓, lactateProd↓, Akt↓, mTOR↓, Dose↝, SIRT6↑, PKM2↓, HK2↓, PFK1↓, ChemoSen↑,
3071- RES,    Resveratrol and Its Anticancer Effects
- Review, Var, NA
chemoPv↑, SIRT1↑, Hif1a↓, VEGF↓, STAT3↓, NF-kB↓, COX2↓, PI3K↓, mTOR↓, NRF2↑, NLRP3↓, H2O2↑, ROS↑, P53↑, PUMA↑, BAX↑,
3096- RES,    Identification of potential target genes of non-small cell lung cancer in response to resveratrol treatment by bioinformatics analysis
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
TumCP↓, Apoptosis↑, Akt↓, mTOR↓, p38↑, MAPK↑, STAT3↓, ROS↑, SIRT1↑, SOX2↓,
3092- RES,    Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action
- Review, BC, MDA-MB-231 - Review, BC, MCF-7
TumCP↓, tumCV↓, TumCI↓, TumMeta↓, *antiOx↑, *cardioP↑, *Inflam↓, *neuroP↑, *Keap1↓, *NRF2↑, *ROS↓, p62↓, IL1β↓, CRP↓, VEGF↓, Bcl-2↓, MMP2↓, MMP9↓, FOXO4↓, POLD1↓, CK2↓, MMP↓, ROS↑, Apoptosis↑, TumCCA↑, Beclin-1↓, Ki-67↓, ATP↓, GlutMet↓, PFK↓, TGF-β↓, SMAD2↓, SMAD3↓, Vim?, Snail↓, Slug↓, E-cadherin↑, EMT↓, Zeb1↓, Fibronectin↓, IGF-1↓, PI3K↓, Akt↓, HO-1↑, eff↑, PD-1↓, CD8+↑, Th1 response↑, CSCs↓, RadioS↑, SIRT1↑, Hif1a↓, mTOR↓,
4663- RES,    Exploring resveratrol’s inhibitory potential on lung cancer stem cells: a scoping review of mechanistic pathways across cancer models
- Review, Var, NA
*antiOx↑, *Inflam↓, *chemoPv↑, CSCs↓, Wnt↓, β-catenin/ZEB1↓, NOTCH↓, PI3K↓, Akt↓, mTOR↓, GSK‐3β↝, Snail↓, HH↓, p‑GSK‐3β↓, N-cadherin↓, EMT↓, CD133↓, CD44↓, ALDH1A1↓, OCT4↓, SOX4↓, Shh↓, Smo↓, Gli1↓, GLI2↓,
3027- RosA,    Rosmarinic acid inhibits proliferation and invasion of hepatocellular carcinoma cells SMMC 7721 via PI3K/AKT/mTOR signal pathway
- in-vitro, HCC, SMMC-7721 cell
TumCP↓, TumCCA↑, Apoptosis↑, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, TumCMig↓, MMPs↓, Vim↓,
3010- RosA,    Exploring the mechanism of rosmarinic acid in the treatment of lung adenocarcinoma based on bioinformatics methods and experimental validation
- in-vitro, Lung, A549 - in-vivo, NA, NA
TumCG↓, Ki-67↓, FABP4↑, PPARα↑, ROS↑, Apoptosis↑, MMP9↓, IGFBP3↓, MMP2↓, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, Gli1↓, PPARγ↑, Cyt‑c↑,
3002- RosA,    Anticancer Effects of Rosemary (Rosmarinus officinalis L.) Extract and Rosemary Extract Polyphenols
- Review, Var, NA
TumCG↓, TumCP↓, TumCCA↑, ChemoSen↑, NRF2↑, PERK↑, SESN2↑, HO-1↑, cl‑Casp3↑, ROS↑, UPR↑, ER Stress↑, CHOP↑, HER2/EBBR2↓, ER-α36↓, PSA↓, BAX↑, AR↓, P-gp↓, Cyt‑c↑, HSP70/HSPA5↑, eff↑, p‑Akt↓, p‑mTOR↓, p‑P70S6K↓, cl‑PARP↑, eff↑,
3003- RosA,    Comprehensive Insights into Biological Roles of Rosmarinic Acid: Implications in Diabetes, Cancer and Neurodegenerative Diseases
- Review, Var, NA - Review, AD, NA - Review, Park, NA
*Inflam↓, *antiOx↑, *neuroP↑, *IL6↓, *IL1β↓, *NF-kB↓, *PGE2↓, *COX2↓, *MMP↑, *memory↑, *ROS↓, *Aβ↓, *HMGB1↓, TumCG↓, MARK4↓, Zeb1↓, MDM2↓, BNIP3↑, ASC↑, NLRP3↓, PI3K↓, Akt↓, Casp1↓, E-cadherin↑, STAT3↓, TLR4↓, MMP↓, ICAM-1↓, AMPK↓, IL6↑, MMP2↓, Warburg↓, Bcl-xL↓, Bcl-2↓, TumCCA↑, EMT↓, TumMeta↓, mTOR↓, HSP27↓, Casp3↑, GlucoseCon↓, lactateProd↓, VEGF↓, p‑p65↓, GIT1↓, FOXM1↓, cycD1/CCND1↓, CDK4↓, MMP9↓, HDAC2↓,
3007- RosA,    Hepatoprotective effects of rosmarinic acid: Insight into its mechanisms of action
- Review, NA, NA
*ROS↓, *lipid-P↓, *Inflam↓, *neuroP↑, *angioG↓, *eff↑, *AST↓, *ALAT↓, *GSSG↓, *eNOS↓, *iNOS↓, *NO↓, *NF-kB↓, *MMP2↓, *MDA↓, *TNF-α↓, *GSH↑, *SOD↑, *IL6↓, *PGE2↓, *COX2↓, *mTOR↑,
4912- Sal,    Salinomycin induces cell death with autophagy through activation of endoplasmic reticulum stress in human cancer cells
- in-vitro, Lung, A549 - in-vitro, Lung, H460 - in-vitro, Lung, Calu-1 - in-vitro, Lung, H157
CSCs↓, TumAuto↑, ER Stress↑, TumCD↑, ATF4↑, CHOP↑, AKT1↓, mTOR↓,
4900- Sal,    Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications
- Review, BC, NA
CSCs↓, Apoptosis↑, TumAuto↑, necrosis↑, TumCP↓, TumCI↓, TumCMig↓, TumCG↓, TumMeta↓, eff↑, Bcl-2↓, cMyc↓, Snail↓, ALDH↓, Myc↓, AR↓, ROS↑, NF-kB↓, PTCH1↓, Smo↓, Gli1↓, GLI2↓, Wnt↓, mTOR↓, GSK‐3β↓, cycD1/CCND1↓, survivin↓, P21↑, p27↑, CHOP↑, Ca+2↑, DNAdam↑, Hif1a↓, VEGF↓, angioG↓, MMP↓, ATP↓, p‑P53↑, γH2AX↑, ChemoSen↑,
4745- Se,  Chemo,    Translational Selenium Nanoparticles Promotes Clinical Non-small-cell Lung Cancer Chemotherapy via Activating Selenoprotein-driven Immune Manipulation
- Study, NSCLC, NA
Risk↓, TumCD↑, mTOR↑, AntiTum↑, ChemoSen↑,
4729- Se,    Selenium regulates Nrf2 signaling to prevent hepatotoxicity induced by hexavalent chromium in broilers
*ROS↓, *NRF2↑, *GPx1↑, *NQO1↑, *mTOR↑, *Beclin-1↓, *ATG5↓, *LC3s↓, *hepatoP↑,
3186- SFN,    A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet
- in-vivo, Nor, NA
*NLRP3↓, *ASC↓, *Casp1↓, *IL1β↓, *ALAT↓, *AST↓, *AMPK↑, *mTOR↓, *P70S6K↓,
1726- SFN,    Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential
- Review, Var, NA
Dose↝, eff↝, IL1β↓, IL6↓, IL12↓, TNF-α↓, COX2↓, CXCR4↓, MPO↓, HSP70/HSPA5↓, HSP90↓, VCAM-1↓, IKKα↓, NF-kB↓, HO-1↑, Casp3↑, Casp7↑, Casp8↑, Casp9↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, CHOP↑, survivin↓, XIAP↓, p38↑, Fas↑, PUMA↑, VEGF↓, Hif1a↓, Twist↓, Zeb1↓, Vim↓, MMP2↓, MMP9↓, E-cadherin↑, N-cadherin↓, Snail↓, CD44↓, cycD1/CCND1↓, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, CDK4↓, CDK6↓, p50↓, P53↑, P21↑, GSH↑, SOD↑, GSTs↑, mTOR↓, Akt↓, PI3K↓, β-catenin/ZEB1↓, IGF-1↓, cMyc↓, CSCs↓,
1458- SFN,    Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma
- Review, Bladder, NA
HDAC↓, eff↓, TumW↓, TumW↓, angioG↓, *toxicity↓, GutMicro↝, AntiCan↑, ROS↑, MMP↓, Cyt‑c↑, Bax:Bcl2↑, Casp3↑, Casp9↑, Casp8∅, cl‑PARP↑, TRAIL↑, DR5↑, eff↓, NRF2↑, ER Stress↑, COX2↓, EGFR↓, HER2/EBBR2↓, ChemoSen↑, NF-kB↓, TumCCA?, p‑Akt↓, p‑mTOR↓, p70S6↓, p19↑, P21↑, CD44↓, CSCs↓,
1475- SFN,  Form,    Combination of Formononetin and Sulforaphane Natural Drug Repress the Proliferation of Cervical Cancer Cells via Impeding PI3K/AKT/mTOR Pathway
- in-vitro, Cerv, HeLa
TumCP↓, PI3K↓, Akt↓, mTOR↓, eff↑, ROS↑,
1479- SFN,    Sulforaphane triggers Sirtuin 3-mediated ferroptosis in colorectal cancer cells via activating the adenosine 5'-monophosphate (AMP)-activated protein kinase/ mechanistic target of rapamycin signaling pathway
- in-vitro, CRC, HCT116
Ferroptosis↑, SIRT3↑, AMPK↑, mTOR↑, tumCV↓, ROS↑, MDA↑, Iron↑,
1513- SFN,  acetaz,    Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis
- in-vitro, BrCC, H720 - in-vivo, BrCC, NA - in-vitro, BrCC, H727
eff↑, tumCV↓, Apoptosis↑, P21↑, PI3K↓, Akt↓, mTOR↓, 5HT↓, NRF2↑,
4203- SIL,    Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer’s Disease and Other Neurological Disorders
- Review, NA, NA
*MAPK↝, *AMPK↝, *NF-kB↓, *mTOR↝, *PI3K↝, *Akt↝, *BioAv↝, *memory↑, *BDNF↑, *TNF-α↓,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
3289- SIL,    Silymarin: a promising modulator of apoptosis and survival signaling in cancer
- Review, Var, NA
*BioAv↝, *BioAv↓, Fas↑, FasL↑, FADD↑, pro‑Casp8↑, Apoptosis↑, DR5↑, Bcl-2↑, BAX↑, Casp3↑, PI3K↓, FOXM1↓, p‑mTOR↓, p‑P70S6K↓, Hif1a↓, Akt↑, angioG↓, STAT3↓, NF-kB↓, lipid-P↓, eff↑, CDK1↓, survivin↓, CycB/CCNB1↓, Mcl-1↓, Casp9↑, AP-1↓, BioAv↑,
3318- SIL,    Pharmaceutical prospects of Silymarin for the treatment of neurological patients: an updated insight
- Review, AD, NA - Review, Park, NA
*hepatoP↑, *neuroP↑, *TLR4↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *memory↑, *cognitive↑, *NRF2↑, *HO-1↑, *ROS↓, *Akt↑, *mTOR↑, *SOD↑, *Catalase↑, *GSH↑, *IL10↑, *IL6↑, *NO↓, *MDA↓, *AChE↓, *MAPK↓, *BDNF↑,
109- SIL,    Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma
- vitro+vivo, RCC, 769-P - in-vitro, RCC, 786-O - in-vitro, RCC, ACHN - in-vitro, RCC, OS-RC-2
HH↓, Gli1↓, GLI2↓, mTOR↓, Bcl-2↓,
965- SK,    Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW-620
Hif1a↓, ROS↓, mTOR↓, p70S6↓, 4E-BP1↓, eIF2α↓, TumCCA↑, TumCP↓, Half-Life↝,
2355- SK,    Pharmacological properties and derivatives of shikonin-A review in recent years
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, TumAuto↑, Necroptosis↑, ROS↑, TrxR1↓, PKM2↓, RIP1↓, RIP3↓, Src↓, FAK↓, PI3K↓, Akt↓, mTOR↓, GRP58↓, MMPs↓, ATF2↓, cl‑PARP↑, Casp3↑, p‑p38↑, p‑JNK↑, p‑ERK↓,
2232- SK,    Shikonin Induces Autophagy and Apoptosis in Esophageal Cancer EC9706 Cells by Regulating the AMPK/mTOR/ULK Axis
- in-vitro, ESCC, EC9706
tumCV↓, TumCMig↓, TumCI↓, TumAuto↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑PARP↑, AMPK↑, mTOR↑, TumVol↓, OS↑, LC3I↑,
2224- SK,    Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells
- in-vitro, HCC, SMMC-7721 cell - in-vitro, HCC, HUH7 - in-vitro, HCC, HepG2
PYCR1↓, PI3K↓, Akt↓, mTOR↓, eff↑,
2415- SK,    Shikonin induces programmed death of fibroblast synovial cells in rheumatoid arthritis by inhibiting energy pathways
- in-vivo, Arthritis, NA
Apoptosis?, TumAuto↑, ROS↑, ATP↓, Glycolysis↓, PI3K↓, Akt↓, mTOR↓, *Apoptosis↓, *Inflam↓, *TNF-α↓, *IL6↓, *IL8↓, *IL10↓, *IL17↓, *hepatoP↑, *RenoP↑, PKM2↓, GLUT1↓, HK2↓,
2199- SK,    Induction of Ferroptosis by Shikonin in Gastric Cancer via the DLEU1/mTOR/GPX4 Axis
- in-vitro, GC, NA
ROS↑, lipid-P↑, Iron↑, MDA↑, GPx4↓, Ferritin↓, DLEU1↓, mTOR↓, Ferroptosis↑,
2197- SK,    Shikonin derivatives for cancer prevention and therapy
- Review, Var, NA
ROS↑, Ca+2↑, BAX↑, Bcl-2↓, MMP9↓, NF-kB↓, PKM2↓, Hif1a↓, NRF2↓, P53↑, DNMT1↓, MDR1↓, COX2↓, VEGF↓, EMT↓, MMP7↓, MMP13↓, uPA↓, RIP1↑, RIP3↑, Casp3↑, Casp7↑, Casp9↑, P21↓, DFF45↓, TRAIL↑, PTEN↑, mTOR↓, AR↓, FAK↓, Src↓, Myc↓, RadioS↑,
318- SNP,    Silver nanoparticles regulate autophagy through lysosome injury and cell hypoxia in prostate cancer cells
- in-vitro, Pca, PC3
lysoM↓, lysosome↓, AMPKα↑, TumAuto↑, mTOR↑,
385- SNP,    Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment
- in-vitro, Hepat, HepG2 - in-vitro, Hepat, WI38
TNF-α↑, IL33↑, mTOR↓, MMP9↓, Bcl-2↓, ROS↑, Apoptosis↑,
3427- TQ,    Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets
ROS⇅, Fas↑, DR5↑, TRAIL↑, Casp3↑, Casp8↑, Casp9↑, P53↑, mTOR↓, Bcl-2↓, BID↓, CXCR4↓, JNK↑, p38↑, MAPK↑, LC3II↑, ATG7↑, Beclin-1↑, AMPK↑, PPARγ↑, eIF2α↓, P70S6K↓, VEGF↓, ERK↓, NF-kB↓, XIAP↓, survivin↓, p65↓, DLC1↑, FOXO↑, TET2↑, CYP1B1↑, UHRF1↓, DNMT1↓, HDAC1↓, IL2↑, IL1↓, IL6↓, IL10↓, IL12↓, TNF-α↓, iNOS↓, COX2↓, 5LO↓, AP-1↓, PI3K↓, Akt↓, cMET↓, VEGFR2↓, CXCL1↓, ITGA5↓, Wnt↓, β-catenin/ZEB1↓, GSK‐3β↓, Myc↓, cycD1/CCND1↓, N-cadherin↓, Snail↓, Slug↓, Vim↓, Twist↓, Zeb1↓, MMP2↓, MMP7↓, MMP9↓, JAK2↓, STAT3↓, NOTCH↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, CDK6↓, CDC2↓, CDC25↓, Mcl-1↓, E2Fs↓, p16↑, p27↑, P21↑, ChemoSen↑,
3397- TQ,    Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
ChemoSen↑, *Half-Life↝, *BioAv↝, *antiOx↑, *Inflam↓, *hepatoP↑, TumCP↓, TumCCA↑, Apoptosis↑, angioG↑, selectivity↑, JNK↑, p38↑, p‑NF-kB↑, ERK↓, PI3K↓, PTEN↑, Akt↓, mTOR↓, EMT↓, Twist↓, E-cadherin↓, ROS⇅, *Catalase↑, *SOD↑, *GSTA1↑, *GPx↑, *PGE2↓, *IL1β↓, *COX2↓, *MMP13↓, MMPs↓, TumMeta↓, VEGF↓, STAT3↓, BAX↑, Bcl-2↑, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, survivin↓, cMyc↓, cycD1/CCND1↓, p27↑, P21↑, GSK‐3β↓, β-catenin/ZEB1↓, chemoP↑,
3425- TQ,    Advances in research on the relationship between thymoquinone and pancreatic cancer
Apoptosis↑, TumCP↓, TumCI↓, TumMeta↓, ChemoSen↑, angioG↓, Inflam↓, NF-kB↓, PI3K↓, Akt↓, TGF-β↓, Jun↓, p38↑, MAPK↑, MMP9↓, PKM2↓, ROS↑, JNK↑, MUC4↓, TGF-β↑, Dose↝, FAK↓, NOTCH↓, PTEN↑, mTOR↓, Warburg↓, XIAP↓, COX2↓, Casp9↑, Ki-67↓, CD34↓, VEGF↓, MCP1↓, survivin↓, Cyt‑c↑, Casp3↑, H4↑, HDAC↓,
3422- TQ,    Thymoquinone, as a Novel Therapeutic Candidate of Cancers
- Review, Var, NA
selectivity↑, P53↑, PTEN↑, NF-kB↓, PPARγ↓, cMyc↓, Casp↑, *BioAv↓, BioAv↝, eff↑, survivin↓, Bcl-xL↓, Bcl-2↓, Akt↓, BAX↑, cl‑PARP↑, CXCR4↓, MMP9↓, VEGFR2↓, Ki-67↓, COX2↓, JAK2↓, cSrc↓, Apoptosis↑, p‑STAT3↓, cycD1/CCND1↓, Casp3↑, Casp7↑, Casp9↑, N-cadherin↓, Vim↓, Twist↓, E-cadherin↑, ChemoSen↑, eff↑, EMT↓, ROS↑, DNMT1↓, eff↑, EZH2↓, hepatoP↑, Zeb1↓, RadioS↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, *NAD↑, *SIRT1↑, SIRT1↓, *Inflam↓, *CRP↓, *TNF-α↓, *IL6↓, *IL1β↓, *eff↑, *MDA↓, *NO↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, PI3K↓, mTOR↓,
3405- TQ,  doxoR,    Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity and the underlying mechanism
- vitro+vivo, NA, NA
*cardioP↑, *NRF2↑, *HO-1↑, *ROS↓, *NQO1↑, *COX2↓, *NOX4↓, *GPx4↑, *FTH1↑, *p‑mTOR↓, *TGF-β↓,
3411- TQ,    Anticancer and Anti-Metastatic Role of Thymoquinone: Regulation of Oncogenic Signaling Cascades by Thymoquinone
- Review, Var, NA
p‑STAT3↓, cycD1/CCND1↓, JAK2↓, β-catenin/ZEB1↓, cMyc↓, MMP7↓, MET↓, p‑Akt↓, p‑mTOR↓, CXCR4↓, Bcl-2↓, BAX↑, ROS↑, Cyt‑c↑, Twist↓, Zeb1↓, E-cadherin↑, p‑p38↑, p‑MAPK↑, ERK↑, eff↑, ERK↓, TumCP↓, TumCMig↓, TumCI↓,
2127- TQ,    Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways
- Review, GBM, NA
chemoP↑, ChemoSen↑, BioAv↑, PTEN↑, PI3K↓, Akt↓, TumCCA↓, NF-kB↓, p‑Akt↓, p65↓, XIAP↓, Bcl-2↓, COX2↓, VEGF↓, mTOR↓, RAS↓, Raf↓, MEK↓, ERK↓, MMP2↓, MMP9↓, TumCMig↓, TumCI↓, Casp↑, cl‑PARP↑, ROS⇅, ROS↑, MMP↓, eff↑, Telomerase↓, DNAdam↑, Apoptosis↑, STAT3↓, RadioS↑,
2084- TQ,    Thymoquinone, as an anticancer molecule: from basic research to clinical investigation
- Review, Var, NA
*ROS↓, *chemoPv↑, ROS↑, ROS⇅, MUC4↓, selectivity↑, AR↓, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, survivin↓, Mcl-1↓, VEGF↓, cl‑PARP↑, ROS↑, HSP70/HSPA5↑, P53↑, miR-34a↑, Rac1↓, TumCCA↑, NOTCH↓, NF-kB↓, IκB↓, p‑p65↓, IAP1↓, IAP2↑, XIAP↓, TNF-α↓, COX2↓, Inflam↓, α-tubulin↓, Twist↓, EMT↓, mTOR↓, PI3K↓, Akt↓, BioAv↓, ChemoSen↑, BioAv↑, PTEN↑, chemoPv↑, RadioS↑, *Half-Life↝, *BioAv↝,
5022- UA,    Ursolic Acid’s Alluring Journey: One Triterpenoid vs. Cancer Hallmarks
- Review, Var, NA
TumCP↓, Apoptosis↑, angioG↑, TumMeta↓, BioAv↓, Hif1a↓, Glycolysis↓, mitResp↓, Akt↓, MAPK↓, ERK↓, mTOR↓, P53↑, P21↑, E2Fs↑, STAT3↓, MMP↓, NLRP3↓, iNOS↓, CHK1↓, Chk2↓, BRCA1↓, E-cadherin↑, N-cadherin↓, Casp↑, p62↓, LC3II↑, Vim↓, ROS↑, CSCs↓, DNAdam↑, GutMicro↑, VEGF↓,
4853- Uro,    Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer
- vitro+vivo, PC, MIA PaCa-2 - in-vitro, NA, PANC1
p‑Akt↓, p‑p70S6↓, TumCG↓, OS↑, PI3K↓, mTOR↓, TumCP↓, TumCMig↓, Apoptosis↑, TAMS↓, Treg lymp↓, Wnt↓, IGF-1↓, *toxicity↓, *BioAv↑, Half-Life↝,
4838- Uro,    The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention
- Review, Var, NA
BioAv↑, Inflam↓, IL6↓, IL1β↓, NOS2↓, p53 Wildtype↑, MDM2↑, Snail↓, E-cadherin↑, N-cadherin↓, Vim↓, NF-kB↓, mTOR↓, p‑Akt↓, selectivity↑, EMT↓,
4835- Uro,    Urolithin A, induces apoptosis and autophagy crosstalk in Oral Squamous Cell Carcinoma via mTOR /AKT/ERK1/2 pathway
- in-vitro, SCC, NA
TumCD↑, ER Stress↑, Akt↓, mtDam↓, p‑mTOR↓, *BioAv↝, ROS↑, TumCCA↑, Apoptosis↑, ERK↓,
4860- Uro,    Urolithins–gut Microbial Metabolites with Potential Health Benefits
- Review, Nor, NA - Review, AD, NA - Review, Park, NA
*ROS↓, *Inflam↓, TumCG↓, *neuroP↑, *cardioP↑, *LDL↓, *BioAv↝, *BioAv↓, *BioAv↑, *SIRT1↑, *mTOR↑, *BDNF↑, *cognitive↑,
4864- Uro,    Therapeutic Potential of Mitophagy-Inducing Microflora Metabolite, Urolithin A for Alzheimer's Disease
- Review, AD, NA
*neuroP↑, *Half-Life↝, *BBB↑, *toxicity↓, *Inflam↓, *Strength↑, *BACE↓, *Aβ↓, *MitoP↑, *SIRT1↑, *SIRT3↑, *AMPK↑, *PGC-1α↑, *mTOR↓, *PARK2↑, *Beclin-1↑, *ROS↓, *GutMicro↑, *Risk↓,
4869- Uro,    Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges
- Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*MitoP↑, *Inflam↓, *antiOx↑, *Risk↓, *Aβ↓, *p‑tau↓, *p62↓, *PARK2↑, *MMP↑, *ROS↓, *Strength↑, *CRP↓, *IL1β↓, *IL6↓, *TNF-α↓, *AMPK↑, *NF-kB↓, *MAPK↓, *p62↑, *NRF2↑, *SOD↑, *Catalase↑, *HO-1↑, *Ferroptosis↓, *lipid-P↓, *Cartilage↑, *PI3K↓, *Akt↓, *mTOR↓, *Apoptosis↓, *neuroP↑, *Bcl-2↓, *BAX↑, *Casp3↑, *ATP↑, *eff↑, *motorD↑, *NLRP3↓, *radioP↑, *BBB↑,
3145- VitC,    Vitamin C inhibits the growth of colorectal cancer cell HCT116 and reverses the glucose‐induced oncogenic effect by downregulating the Warburg effect
- in-vitro, CRC, HCT116
Warburg↓, TumCG↓, Glycolysis↓, GlucoseCon↓, ATP↓, lactateProd↓, selectivity↑, GLUT1↓, PKM2↓, LDHA↓, mTOR↓,
2366- VitD3,    Vitamin D3 decreases glycolysis and invasiveness, and increases cellular stiffness in breast cancer cells
- in-vitro, BC, MCF-7
Glycolysis↓, tumCV↓, Apoptosis↑, mTOR↓, AMPK↑, EMT↓, E-cadherin↑, F-actin↑, Vim↓,
2365- VitD3,    Vitamin D Affects the Warburg Effect and Stemness Maintenance of Non- Small-Cell Lung Cancer Cells by Regulating the PI3K/AKT/mTOR Signaling Pathway
- in-vitro, Lung, A549 - in-vitro, Lung, H1975 - in-vivo, NA, NA
Glycolysis↓, Warburg↓, GLUT1↓, LDHA↓, HK2↓, PKM2↓, OCT4↓, SOX2↓, Nanog↓, PI3K↓, Akt↓, mTOR↓,
2425- γ-Toc,    Anticancer Effects of γ-Tocotrienol Are Associated with a Suppression in Aerobic Glycolysis
- in-vitro, NA, MCF-7 - in-vivo, NA, NA
TumCG↓, GlucoseCon↓, ATP↓, lactateProd↓, Glycolysis↓, HK2↓, PFK↓, PKM2↓, LDHA↓, Akt↓, p‑mTOR↓, cMyc↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 254

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

chemoPv↑, 6,  

Redox & Oxidative Stress ⓘ

antiOx↓, 2,   antiOx↑, 4,   Catalase↓, 2,   Copper↑, 1,   CYP1A1↓, 1,   CYP1A1↑, 1,   Fenton↑, 2,   Ferroptosis↑, 8,   GPx↓, 2,   GPx4↓, 3,   GSH↓, 14,   GSH↑, 4,   GSR↓, 2,   GSTP1/GSTπ↓, 1,   GSTs↓, 2,   GSTs↑, 2,   H2O2↓, 1,   H2O2↑, 4,   HO-1↓, 5,   HO-1↑, 12,   hyperG↓, 1,   Iron↑, 6,   i-Iron↓, 1,   Keap1↓, 1,   Keap1↑, 1,   Keap1↝, 1,   lipid-P↓, 5,   lipid-P↑, 7,   MDA↓, 1,   MDA↑, 7,   MPO↓, 1,   NADPH/NADP+↓, 1,   NOX4↑, 1,   NQO1↓, 1,   NQO1↑, 2,   NRF2↓, 13,   NRF2↑, 15,   NRF2↝, 2,   p‑NRF2↓, 1,   OXPHOS↓, 2,   OXPHOS↑, 2,   OXPHOS↝, 1,   mt-OXPHOS↑, 1,   PARK2↑, 1,   Prx4↑, 1,   PYCR1↓, 2,   ROS↓, 16,   ROS↑, 120,   ROS⇅, 6,   ROS↝, 1,   i-ROS↑, 1,   mt-ROS↑, 1,   SIRT3↓, 1,   SIRT3↑, 4,   SOD↓, 3,   SOD↑, 6,   SOD1↑, 2,   SOD2↓, 3,   SOD2↑, 1,   TKT↝, 1,   TrxR↓, 5,   TrxR1↓, 1,   VitC↓, 1,   VitE↓, 1,  

Metal & Cofactor Biology ⓘ

Ferritin↓, 3,   FTH1↓, 2,   KLF5↓, 1,   NCOA4↑, 2,   Tf↑, 1,   TfR1/CD71↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 5,   ATP↓, 13,   mt-ATP↓, 1,   BOK↑, 1,   CDC2↓, 4,   CDC25↓, 8,   EGF↓, 4,   EGF↑, 1,   FGFR1↓, 2,   MEK↓, 4,   MEK↑, 1,   mitResp↓, 4,   MMP↓, 34,   MMP↑, 1,   MPT↑, 1,   mtDam↓, 1,   mtDam↑, 3,   OCR↓, 4,   OCR↑, 1,   PINK1↑, 1,   Raf↓, 3,   e-Raf↓, 1,   XIAP↓, 13,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 1,   ACC↑, 3,   p‑ACC-α↑, 1,   ACLY↓, 3,   adiP↑, 1,   AKT1↓, 1,   ALAT↓, 1,   AMP↓, 2,   AMPK↓, 3,   AMPK↑, 38,   AMPK↝, 1,   p‑AMPK↑, 6,   ATG7↑, 4,   CAIX↓, 1,   Cav1↓, 1,   cMyc↓, 24,   ECAR↓, 4,   FABP4↑, 1,   FASN↓, 3,   FASN↑, 1,   FBPase↑, 1,   FDG↓, 1,   G6PD↓, 1,   GAPDH↓, 1,   GLO-I↓, 1,   GLS↓, 1,   glucoNG↑, 1,   GlucoseCon↓, 17,   GlutMet↓, 2,   glyC↓, 1,   Glycolysis↓, 32,   p‑GS3Kβ↓, 1,   HK2↓, 15,   lactateProd↓, 16,   LDH↓, 6,   LDH↑, 2,   LDHA↓, 9,   LDL↓, 2,   MCU↓, 1,   NAD↓, 1,   NAD↑, 1,   NADH:NAD↓, 1,   NADPH↓, 3,   PDH↑, 3,   PDK1↓, 5,   PDK3↑, 1,   PDKs↓, 1,   PFK↓, 4,   PFK1↓, 3,   PFK2↓, 1,   PFKP↓, 1,   PI3K/Akt↓, 5,   PI3k/Akt/mTOR↓, 3,   PKM2↓, 25,   PKM2:PKM1↓, 1,   POLD1↓, 1,   PPARα↓, 1,   PPARα↑, 1,   PPARγ↓, 2,   PPARγ↑, 5,   Pyruv↓, 1,   R5P↝, 1,   p‑S6↓, 2,   p‑S6K↓, 2,   SIRT1↓, 2,   SIRT1↑, 8,   SREBP1↓, 1,   TCA↑, 1,   Warburg↓, 11,  

Cell Death ⓘ

Akt↓, 118,   Akt↑, 4,   Akt↝, 2,   p‑Akt↓, 41,   p‑Akt↝, 1,   APAF1↑, 2,   Apoptosis?, 1,   Apoptosis↑, 74,   Apoptosis↝, 2,   ASK1↑, 2,   ATF2↓, 1,   BAD↓, 1,   BAD↑, 4,   Bak↑, 5,   BAX↑, 52,   BAX↝, 1,   Bax:Bcl2↑, 6,   Bcl-2↓, 56,   Bcl-2↑, 2,   Bcl-2↝, 1,   cl‑Bcl-2↓, 1,   Bcl-xL↓, 14,   Bcl-xL↝, 1,   BID↓, 1,   BID↑, 2,   BIM↓, 1,   BIM↑, 6,   Casp↑, 14,   Casp1↓, 2,   Casp10↑, 1,   Casp2↑, 1,   Casp3↓, 3,   Casp3↑, 65,   Casp3↝, 1,   cl‑Casp3↓, 1,   cl‑Casp3↑, 7,   proCasp3↓, 1,   Casp7↑, 8,   Casp8↑, 18,   Casp8∅, 1,   cl‑Casp8↑, 2,   pro‑Casp8↑, 1,   Casp9↑, 36,   cl‑Casp9↓, 1,   cl‑Casp9↑, 3,   cFLIP↓, 6,   Chk2↓, 1,   p‑Chk2↑, 1,   CK2↓, 1,   Cyt‑c↑, 39,   Cyt‑c↝, 1,   Diablo↑, 8,   DR4↑, 1,   DR5↓, 1,   DR5↑, 14,   FADD↑, 2,   Fap1↓, 1,   Fas↑, 9,   FasL↑, 5,   Ferroptosis↑, 8,   GRP58↓, 1,   HGF/c-Met↓, 1,   hTERT/TERT↓, 1,   IAP1↓, 3,   IAP2↓, 1,   IAP2↑, 1,   ICAD↓, 1,   iNOS↓, 9,   JNK↑, 10,   JNK↝, 1,   p‑JNK↑, 3,   MAPK↓, 12,   MAPK↑, 7,   MAPK↝, 1,   p‑MAPK↑, 1,   Mcl-1↓, 18,   MCT1↓, 1,   MDM2↓, 4,   MDM2↑, 1,   p‑MDM2↓, 1,   MKP1↓, 1,   MKP2↓, 1,   Myc↓, 5,   NAIP↓, 1,   Necroptosis↑, 1,   necrosis↑, 2,   oncosis↑, 2,   p27↓, 1,   p27↑, 17,   p38↓, 3,   p38↑, 10,   p‑p38↑, 3,   PUMA↑, 2,   RIP1↓, 1,   RIP1↑, 1,   survivin↓, 27,   Telomerase↓, 3,   TNFR 1↑, 1,   TRAIL↑, 5,   TRAILR↑, 2,   TRPV1↑, 2,   TumCD↑, 4,   YAP/TEAD↓, 1,   β-TRCP↑, 1,  

Kinase & Signal Transduction mTOR, MAP" style="cursor:help;color:#555;font-weight:normal;">ⓘ

AMPKα↑, 5,   CaMKII ↓, 2,   cSrc↓, 2,   HER2/EBBR2↓, 8,   p‑HER2/EBBR2↓, 1,   p70S6↓, 5,   p‑p70S6↓, 2,   SOX9↓, 1,   Sp1/3/4↓, 5,   TSC2↑, 3,   p‑TSC2↑, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 5,   DLEU1↓, 1,   EZH2↓, 3,   H3↓, 1,   ac‑H3↑, 1,   H4↓, 1,   H4↑, 1,   ac‑H4↑, 1,   HATs↑, 1,   miR-21↓, 1,   miR-21↑, 1,   other↓, 3,   p‑pRB↓, 1,   tumCV↓, 21,  

Protein Folding & ER Stress ⓘ

ATF6↑, 2,   ATFs↑, 1,   CHOP↑, 18,   eIF2α↓, 2,   eIF2α↑, 2,   p‑eIF2α↑, 3,   ER Stress↓, 2,   ER Stress↑, 28,   ERStress↑, 1,   GRP78/BiP↓, 1,   GRP78/BiP↑, 10,   HSF1↓, 2,   HSP27↓, 4,   HSP27↝, 1,   HSP70/HSPA5↓, 5,   HSP70/HSPA5↑, 3,   HSP70/HSPA5↝, 1,   HSP90↓, 4,   IRE1↑, 4,   PERK↑, 3,   p‑PERK↑, 1,   UPR↑, 4,   XBP-1↓, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes ⓘ

ATG3↑, 3,   ATG5↑, 5,   Beclin-1↓, 2,   Beclin-1↑, 9,   BNIP3↑, 2,   LC3‑Ⅱ/LC3‑Ⅰ↑, 5,   LC3A↑, 1,   LC3B↓, 1,   LC3B↑, 1,   LC3B-II↑, 4,   LC3I↓, 1,   LC3I↑, 1,   LC3II↑, 10,   LC3s↓, 1,   LC3s↑, 1,   lysoM↓, 1,   lysosome↓, 1,   p62↓, 10,   p62↑, 5,   SESN2↑, 2,   TumAuto↓, 1,   TumAuto↑, 35,  

DNA Damage & Repair ⓘ

ATM↑, 1,   p‑ATM↑, 1,   p‑ATR↑, 1,   BRCA1↓, 1,   CHK1↓, 1,   p‑CHK1↑, 1,   CYP1B1↑, 1,   DFF45↓, 1,   DFF45↑, 1,   DNAdam↑, 21,   DNMT1↓, 4,   DNMTs↓, 1,   HR↓, 1,   NBR2↑, 1,   p16↑, 3,   P53?, 1,   P53↓, 1,   P53↑, 42,   P53↝, 1,   p‑P53↑, 2,   p53 Wildtype↑, 1,   p53 Wildtype∅, 1,   p73↑, 1,   PARP↓, 2,   PARP↑, 7,   cl‑PARP↑, 29,   PARP1↑, 1,   PCNA↓, 9,   RAD51↓, 1,   SIRT6↑, 1,   UHRF1↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 7,   CDK1↑, 1,   p‑CDK1↓, 1,   CDK2↓, 19,   CDK2↑, 2,   CDK4↓, 22,   CDK4↑, 3,   Cyc↓, 1,   Cyc↝, 1,   cycA1/CCNA1↓, 6,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 11,   cycD1/CCND1↓, 38,   cycD1/CCND1↝, 1,   CycD3↓, 1,   cycE/CCNE↓, 13,   cycE1↓, 2,   E2Fs↓, 1,   E2Fs↑, 1,   p19↑, 2,   P21↓, 2,   P21↑, 33,   P21↝, 1,   RB1↓, 1,   RB1↑, 1,   p‑RB1↓, 2,   Securin↓, 1,   TAp63α↑, 1,   TumCCA?, 1,   TumCCA↓, 2,   TumCCA↑, 64,  

Proliferation, Differentiation & Cell State ⓘ

4E-BP1↓, 2,   p‑4E-BP1↓, 2,   ALDH↓, 2,   ALDH1A1↓, 1,   BMI1↓, 2,   CD133↓, 3,   CD24↓, 2,   CD34↓, 2,   CD44↓, 8,   cDC2↓, 1,   cFos↓, 6,   cFos↑, 1,   cMET↓, 3,   p‑cMET↑, 1,   CREBBP↓, 1,   CSCs↓, 19,   CSCsMark↓, 1,   Diff↑, 1,   EIF4E↓, 1,   EMT↓, 45,   EMT↑, 2,   ERK↓, 25,   ERK↑, 7,   ERK↝, 1,   p‑ERK↓, 5,   p‑ERK↑, 1,   FGF↓, 1,   FOXM1↓, 4,   FOXO↑, 1,   FOXO1↑, 1,   FOXO3↑, 1,   p‑FOXO3↓, 1,   FOXO4↓, 1,   Gli1↓, 10,   GSK‐3β↓, 9,   GSK‐3β↑, 1,   GSK‐3β↝, 1,   p‑GSK‐3β↓, 1,   p‑GSK‐3β↑, 1,   HDAC↓, 11,   HDAC∅, 1,   HDAC1↓, 3,   HDAC10↓, 1,   HDAC10↑, 1,   HDAC2↓, 3,   HDAC3↓, 2,   HDAC8↓, 1,   HH↓, 8,   IGF-1↓, 9,   IGF-1R↓, 2,   IGFBP1↑, 2,   IGFBP3↓, 1,   IGFBP3↑, 1,   IGFBP7↑, 1,   Jun↓, 1,   Let-7↑, 1,   miR-34a↑, 2,   mTOR↓, 175,   mTOR↑, 13,   mTOR⇅, 1,   mTOR↝, 3,   mTOR∅, 1,   p‑mTOR↓, 34,   p‑mTOR↑, 2,   mTORC1↓, 4,   mTORC2↓, 2,   mTORC2↑, 1,   Nanog↓, 3,   Nestin↓, 1,   NOTCH↓, 10,   NOTCH1↓, 5,   NOTCH1↑, 2,   NOTCH3↓, 1,   OCT4↓, 5,   P70S6K↓, 7,   P70S6K↑, 1,   p‑P70S6K↓, 5,   p‑P70S6K↑, 1,   p85S6K↓, 1,   p‑P90RSK↑, 1,   PI3K↓, 80,   PI3K↑, 3,   PI3K↝, 2,   p‑PI3K↓, 4,   PRKCG↑, 1,   PTCH1↓, 3,   PTEN↓, 2,   PTEN↑, 21,   PTEN↝, 1,   RAS↓, 8,   RAS↑, 1,   RPS6KA1↓, 1,   Shh↓, 5,   Smo↓, 6,   SOX2↓, 4,   Src↓, 2,   p‑Src↓, 1,   STAT↓, 2,   STAT1↓, 1,   STAT3↓, 40,   p‑STAT3↓, 7,   p‑STAT3↑, 1,   STAT6↓, 2,   p‑STAT6↓, 1,   Sufu↓, 1,   TCF↑, 1,   TCF-4↓, 2,   TOP1?, 1,   TOP1↓, 3,   TOP2↓, 4,   TumCG↓, 39,   TumCG↑, 1,   Wnt?, 1,   Wnt↓, 22,   Wnt/(β-catenin)↓, 6,   Wnt/(β-catenin)↑, 1,  

Migration ⓘ

5LO↓, 3,   AntiAg↓, 1,   AntiAg↑, 2,   AP-1↓, 7,   AP-1↝, 1,   AXL↓, 1,   CA↓, 1,   Ca+2↓, 3,   Ca+2↑, 16,   Ca+2↝, 1,   i-Ca+2?, 1,   CAFs/TAFs↓, 2,   cal2↓, 1,   CD31↓, 2,   Cdc42↓, 1,   CDK4/6↓, 1,   CEA↓, 1,   CLDN1↓, 2,   CLDN2↓, 1,   COL1↓, 1,   COL3A1↓, 1,   CXCL12↓, 1,   DLC1↑, 1,   E-cadherin↓, 6,   E-cadherin↑, 27,   ER-α36↓, 1,   F-actin↑, 1,   FAK↓, 8,   p‑FAK↓, 1,   Fibronectin↓, 4,   Furin↓, 1,   GIT1↓, 1,   GLI2↓, 5,   ITGA5↓, 1,   ITGB1↓, 1,   ITGB1↑, 1,   Ki-67↓, 10,   KLF2↓, 1,   LEF1↓, 1,   LysoPr↑, 1,   MARK4↓, 1,   MET↓, 3,   p‑MET↓, 1,   miR-139-5p↑, 1,   miR-206↑, 1,   MMP-10↓, 1,   MMP1↓, 3,   MMP13↓, 2,   MMP2↓, 43,   MMP2↑, 1,   MMP2↝, 1,   MMP3↓, 4,   MMP7↓, 9,   MMP9↓, 46,   MMP9↑, 2,   MMP9:TIMP1↓, 1,   MMPs↓, 14,   MUC4↓, 2,   N-cadherin↓, 20,   NCAM↑, 1,   NEDD9↓, 1,   PDGF↓, 2,   PKA↓, 1,   PKCδ↓, 3,   Rac1↓, 2,   RAGE↓, 2,   Rho↓, 3,   Rho↑, 1,   RIP3↓, 1,   RIP3↑, 1,   ROCK1↓, 4,   ROCK1↑, 1,   Slug↓, 6,   SMAD2↓, 1,   p‑SMAD2↓, 1,   SMAD3↓, 2,   p‑SMAD4↓, 1,   Snail↓, 22,   SOX4↓, 1,   SOX4↑, 1,   talin↓, 1,   TET1↓, 1,   TET1↑, 1,   TGF-β↓, 11,   TGF-β↑, 2,   TIMP1↓, 1,   TIMP1↑, 1,   TIMP2↓, 1,   TIMP2↑, 2,   Treg lymp↓, 1,   TSC1↑, 1,   TSP-1↑, 3,   TumCA↓, 2,   TumCI?, 1,   TumCI↓, 40,   TumCMig↓, 33,   TumCMig↑, 2,   TumCP↓, 57,   TumMeta↓, 23,   Twist↓, 16,   Tyro3↓, 1,   uPA↓, 15,   uPAR↓, 1,   VCAM-1↓, 2,   Vim?, 1,   Vim↓, 23,   Vim↑, 1,   vinculin↓, 1,   Zeb1↓, 7,   ZO-1↑, 2,   α-tubulin↓, 1,   ac‑α-tubulin↑, 1,   β-catenin/ZEB1↓, 27,   β-catenin/ZEB1↑, 2,   β-catenin/ZEB1↝, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 35,   angioG↑, 2,   ATF4↓, 1,   ATF4↑, 7,   ATF4↝, 1,   EGFR↓, 25,   EGFR↑, 1,   EGFR↝, 1,   EGR4↓, 1,   eNOS↓, 1,   HIF-1↓, 5,   Hif1a↓, 39,   KDR/FLK-1↓, 1,   LOX1↓, 1,   NO↓, 3,   NO↑, 1,   NO↝, 1,   TAMS↓, 1,   VEGF↓, 52,   VEGF↑, 1,   VEGF↝, 1,   VEGFR2↓, 8,  

Barriers & Transport ⓘ

AQPs↓, 1,   BBB↓, 1,   BBB↑, 3,   GLUT1↓, 17,   P-gp↓, 8,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   ASC↑, 1,   CD4+↓, 1,   COX2↓, 39,   COX2↑, 2,   COX2↝, 1,   CRP↓, 3,   CXCL1↓, 1,   CXCR4↓, 10,   ICAM-1↓, 3,   IFN-γ↓, 2,   IFN-γ↑, 1,   IKKα↓, 7,   IKKα↑, 1,   p‑IKKα↓, 2,   IL1↓, 3,   IL10↓, 7,   IL12↓, 2,   IL1α↓, 1,   IL1β↓, 9,   IL2↓, 1,   IL2↑, 4,   IL33↑, 1,   IL6↓, 22,   IL6↑, 1,   IL6↝, 1,   IL8↓, 3,   Inflam↓, 13,   IκB↓, 1,   IκB↑, 1,   p‑IκB↓, 1,   JAK↓, 3,   JAK1↓, 3,   JAK2↓, 8,   p‑JAK2↓, 1,   M2 MC↓, 1,   MCP1↓, 2,   MDSCs↓, 1,   MIP2↓, 1,   NF-kB↓, 64,   NF-kB↑, 1,   NF-kB↝, 2,   p‑NF-kB↓, 1,   p‑NF-kB↑, 1,   p50↓, 1,   p65↓, 4,   p‑p65↓, 3,   PD-1↓, 3,   PD-L1↓, 5,   PGE2↓, 11,   PSA↓, 3,   PSA↝, 1,   Th1 response↑, 1,   TLR4↓, 3,   TNF-α↓, 17,   TNF-α↑, 2,   TNF-α↝, 1,  

Synaptic & Neurotransmission ⓘ

5HT↓, 1,   ADAM10↓, 1,   MAOA↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 4,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 10,   AR↝, 1,   CDK6↓, 11,   CDK6↑, 3,   ERα/ESR1↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 18,   BioAv↑, 16,   BioAv↝, 5,   BioEnh↑, 1,   ChemoSen↑, 51,   Dose?, 1,   Dose↑, 2,   Dose↝, 7,   Dose∅, 2,   eff↓, 16,   eff↑, 67,   eff↝, 4,   eff∅, 1,   Half-Life↓, 3,   Half-Life↝, 9,   Half-Life∅, 1,   MDR1↓, 4,   MRP1↓, 1,   P450↓, 1,   RadioS↑, 21,   selectivity↑, 33,   TET2↑, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   ALP↓, 1,   AR↓, 10,   AR↝, 1,   BG↓, 3,   BMPs↑, 2,   BRCA1↓, 1,   CEA↓, 1,   CRP↓, 3,   E6↓, 3,   E7↓, 3,   EGFR↓, 25,   EGFR↑, 1,   EGFR↝, 1,   ERα/ESR1↓, 1,   EZH2↓, 3,   Ferritin↓, 3,   FOXM1↓, 4,   GutMicro↑, 4,   GutMicro↝, 1,   HemoG↓, 1,   HER2/EBBR2↓, 8,   p‑HER2/EBBR2↓, 1,   hTERT/TERT↓, 1,   IL6↓, 22,   IL6↑, 1,   IL6↝, 1,   Ki-67↓, 10,   LDH↓, 6,   LDH↑, 2,   Myc↓, 5,   NOS2↓, 1,   NSE↓, 1,   PD-L1↓, 5,   PSA↓, 3,   PSA↝, 1,   RAGE↓, 2,  

Functional Outcomes ⓘ

AntiCan↑, 14,   AntiTum↑, 8,   cachexia↓, 1,   cardioP↑, 4,   chemoP↑, 9,   ChemoSideEff↓, 3,   hepatoP↑, 2,   neuroP↑, 5,   OS↑, 7,   QoL↑, 1,   radioP↑, 1,   RenoP↑, 4,   Risk↓, 3,   toxicity↓, 4,   toxicity↝, 3,   toxicity∅, 1,   TumVol↓, 4,   TumW↓, 7,  

Infection & Microbiome ⓘ

CD8+↑, 1,   Sepsis↓, 1,  
Total Targets: 804

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

chemoPv↑, 3,  

Redox & Oxidative Stress ⓘ

antiOx?, 1,   antiOx↓, 1,   antiOx↑, 25,   mt-antiOx↑, 1,   Catalase↑, 14,   Ferroptosis↓, 1,   GPx↑, 9,   GPx1↑, 2,   GPx4↑, 1,   GSH↑, 11,   GSSG↓, 1,   GSTA1↑, 1,   GSTs↑, 1,   H2O2↓, 1,   HO-1↑, 11,   Keap1↓, 2,   Keap1↑, 1,   lipid-P↓, 7,   MDA↓, 8,   MPO↓, 1,   NOX4↓, 1,   NQO1↑, 4,   NRF2↑, 20,   PARK2↑, 2,   ROS↓, 38,   mt-ROS↓, 2,   SIRT3↑, 3,   SOD↑, 14,  

Metal & Cofactor Biology ⓘ

FTH1↑, 1,   IronCh↓, 1,   IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 2,   Insulin↓, 1,   MMP↑, 2,   MMP∅, 1,   OCR↑, 1,   PGC-1α↑, 4,  

Core Metabolism/Glycolysis ⓘ

adiP↑, 1,   ALAT↓, 4,   AMPK↓, 1,   AMPK↑, 9,   AMPK↝, 1,   p‑AMPK↑, 1,   p‑cMyc↑, 1,   ECAR↓, 1,   FASN↓, 1,   FGF21↑, 1,   glucose↓, 1,   GlucoseCon↑, 3,   Glycolysis↓, 1,   Glycolysis↑, 1,   H2S↑, 1,   HK2↑, 1,   LDL↓, 3,   NAD↑, 1,   NADPH↓, 4,   PFK↑, 1,   PKM2↑, 1,   PPARα↑, 1,   PPARγ↓, 1,   PPARγ↑, 1,   p‑PPARγ↓, 1,   SIRT1↑, 6,  

Cell Death ⓘ

Akt↓, 5,   Akt↑, 6,   Akt↝, 1,   p‑Akt↓, 2,   p‑Akt↑, 1,   Apoptosis↓, 5,   BAD↓, 1,   BAX↓, 1,   BAX↑, 1,   Bcl-2↓, 1,   Bcl-2↑, 1,   BMP2↑, 1,   Casp1↓, 1,   Casp12↓, 1,   Casp3↓, 5,   Casp3↑, 1,   Casp3∅, 1,   Cyt‑c∅, 1,   Ferroptosis↓, 1,   HGF/c-Met↑, 1,   iNOS↓, 5,   JNK↓, 1,   p‑JNK↓, 1,   p‑JNK↑, 1,   MAPK↓, 4,   MAPK↑, 1,   MAPK↝, 1,   p38↓, 1,   Pyro↓, 1,  

Kinase & Signal Transduction mTOR, MAP" style="cursor:help;color:#555;font-weight:normal;">ⓘ

p‑p70S6↓, 1,  

Transcription & Epigenetics ⓘ

Ach↑, 3,   other↓, 4,   other↑, 1,   other↝, 1,  

Protein Folding & ER Stress ⓘ

CHOP↓, 2,   ER Stress↓, 2,   GRP78/BiP↓, 1,   HSP90↑, 1,  

Autophagy & Lysosomes ⓘ

ATG5↓, 1,   Beclin-1↓, 1,   Beclin-1↑, 3,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3II↑, 1,   LC3s↓, 1,   MitoP↑, 2,   p62↓, 2,   p62↑, 1,  

DNA Damage & Repair ⓘ

DNArepair↑, 1,   p16↓, 1,   P53↓, 1,  

Cell Cycle & Senescence ⓘ

P21↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

cFos↑, 1,   Diff↑, 1,   ERK↓, 1,   ERK↑, 2,   p‑ERK↑, 2,   FGF↑, 1,   FOXO3↑, 1,   GSK‐3β↓, 1,   HDAC2↓, 1,   IGF-1↓, 1,   mTOR↓, 14,   mTOR↑, 8,   mTOR↝, 2,   p‑mTOR↓, 5,   p‑mTOR↑, 2,   P70S6K↓, 3,   p‑P70S6K↑, 1,   PI3K↓, 3,   PI3K↑, 2,   PI3K↝, 1,   PTEN↓, 1,   RAS↓, 1,  

Migration ⓘ

5LO↓, 1,   AntiAg↑, 5,   APP↓, 1,   Ca+2↓, 1,   Ca+2↑, 1,   Cartilage↑, 1,   CD31↑, 1,   CDK5↓, 1,   MMP-10↓, 1,   MMP1↓, 1,   MMP13↓, 1,   MMP2↓, 1,   MMP3↓, 1,   MMP9↓, 1,   MMPs↑, 1,   N-cadherin↑, 1,   PDGF↑, 1,   PKA↑, 1,   PKCδ↓, 1,   p‑Rac1↓, 1,   Rho↓, 1,   SMAD3↓, 1,   TGF-β↓, 2,   TGF-β1↓, 1,   TIMP1↑, 1,   TIMP2↑, 1,   TXNIP↓, 1,   α-SMA↓, 1,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   ATF4↑, 1,   eNOS↓, 1,   NO↓, 6,   NO↑, 1,   VEGF↑, 3,  

Barriers & Transport ⓘ

BBB↑, 6,   GLUT4↑, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   COX1↓, 1,   COX2↓, 11,   CRP↓, 2,   HMGB1↓, 1,   IKKα↑, 1,   IL1↑, 1,   IL10↓, 2,   IL10↑, 6,   IL17↓, 2,   IL18↓, 1,   IL1β↓, 14,   IL23↓, 1,   IL6↓, 15,   IL6↑, 1,   IL8↓, 4,   Inflam↓, 36,   Inflam↑, 1,   MCP1↓, 1,   NF-kB↓, 13,   p‑NF-kB↓, 1,   PGE2↓, 7,   PGE2↑, 1,   Th1 response↓, 1,   Th2↑, 2,   TLR2↓, 2,   TLR4↓, 3,   TNF-α↓, 16,   TNF-α↑, 1,  

Synaptic & Neurotransmission ⓘ

5HT↑, 1,   AChE↓, 4,   BDNF↑, 8,   ChAT↑, 2,   NGF↑, 1,   p‑tau↓, 3,  

Protein Aggregation ⓘ

Aβ↓, 9,   BACE↓, 2,   NLRP3↓, 6,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 10,   BioAv↑, 6,   BioAv↝, 9,   BioEnh↑, 2,   Dose↑, 1,   eff↑, 9,   eff↝, 1,   Half-Life↓, 1,   Half-Life↝, 7,   Half-Life∅, 2,  

Clinical Biomarkers ⓘ

ALAT↓, 4,   ALP↓, 2,   AST↓, 5,   BG↓, 1,   BMD↑, 1,   CRP↓, 2,   GutMicro↑, 3,   IL6↓, 15,   IL6↑, 1,  

Functional Outcomes ⓘ

AntiAge↑, 1,   AntiCan↓, 1,   AntiCan↑, 1,   cardioP↑, 11,   chemoP↑, 1,   cognitive↑, 11,   hepatoP↑, 8,   memory↑, 13,   motorD↑, 1,   neuroP↑, 25,   OS↑, 2,   radioP↑, 1,   RenoP↑, 3,   Risk↓, 3,   Strength↑, 2,   toxicity↓, 11,   toxicity↑, 1,   toxicity∅, 2,  

Infection & Microbiome ⓘ

Bacteria↓, 1,   Sepsis↓, 2,  
Total Targets: 252

Scientific Paper Hit Count for: mTOR, mammalian target of rapamycin
16 Curcumin
12 Fisetin
12 Quercetin
11 Berberine
9 Thymoquinone
9 Baicalein
8 Apigenin (mainly Parsley)
8 Honokiol
8 Resveratrol
7 Alpha-Lipoic-Acid
7 Magnetic Fields
7 EGCG (Epigallocatechin Gallate)
7 Shikonin
6 Artemisinin
6 diet FMD Fasting Mimicking Diet
6 Lycopene
6 Sulforaphane (mainly Broccoli)
6 Urolithin
5 Chemotherapy
5 Magnolol
5 Piperlongumine
5 Rosmarinic acid
5 Silymarin (Milk Thistle) silibinin
4 Ashwagandha(Withaferin A)
4 Citric Acid
4 Metformin
4 Pterostilbene
3 5-fluorouracil
3 Coenzyme Q10
3 Capsaicin
3 Chrysin
3 salinomycin
3 Hydrogen Gas
3 Naringin
2 Allicin (mainly Garlic)
2 Betulinic acid
2 Boswellia (frankincense)
2 Propolis -bee glue
2 Ursolic acid
2 Dichloroacetate
2 Deguelin
2 Ellagic acid
2 HydroxyTyrosol
2 itraconazole
2 Luteolin
2 Magnetic Field Rotating
2 Cisplatin
2 Selenium
2 Silver-NanoParticles
2 Vitamin D3
1 Andrographis
1 2-DeoxyGlucose
1 Astragalus
1 Butyrate
1 Baicalin
1 Carnosic acid
1 Trastuzumab
1 Crocetin
1 diet Methionine-Restricted Diet
1 diet Short Term Fasting
1 Emodin
1 Ferulic acid
1 flavonoids
1 Gambogic Acid
1 Garcinol
1 HydroxyCitric Acid
1 Huperzine A/Huperzia serrata
1 Ivermectin
1 Sorafenib (brand name Nexavar)
1 Juglone
1 Laetrile B17 Amygdalin
1 Methylene blue
1 MCToil
1 Niclosamide (Niclocide)
1 Oleuropein
1 Oleocanthal
1 Parthenolide
1 sericin
1 Phenethyl isothiocyanate
1 Piperine
1 Plumbagin
1 Formononetin
1 acetazolamide
1 doxorubicin
1 Vitamin C (Ascorbic Acid)
1 γ-Tocotrienol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:209  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page